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ABSTRACT
The control of oxidative metabolism was studied using carbon-13 (13C)
nuclear magnetic resonance (NMR) spectroscopy to determine the rate-
limiting steps in 13C labeling of glutamate. 13 C NMR spectra were acquired
from isolated rabbit hearts perfused with either 2.5 mM [2- 13C] acetate or 2.5
mM [2- 13 C] butyrate, and with or without KCl arrest. The tricarboxylic acid
(TCA) cycle flux and the interconversion rate between (-ketoglutarate and
glutamate were determined by least-square fitting of a kinetic model to NMR
data. Rates were compared to flux through glutamate-oxaloacetate
transaminase (GOT). Despite similar oxygen use, hearts oxidizing butyrate
showed delayed incorporation of 13 C label into glutamate and lower TCA
cycle flux due to the influence of n-oxidation: 8.0±0.2 ýtmoles/min/g dry
weight with butyrate versus 10.5±0.4 with acetate at normal workload; 1.7±0.1
with butyrate versus 2.9±0.1 with acetate at potassium arrest (mean±SD). The
interconversion rate between ca-ketoglutarate and glutamate ranged from
4.1±0.9 (butyrate+KC1) to 10.7±1.0 gmoles/min/g dry weight (acetate), at least
20-fold slower than the flux through GOT, and this proved to be the rate-
limiting step in glutamate labeling. The results indicate that dynamic 13 C
NMR is sensitive not only to TCA cycle flux but also to metabolite transport
rate across the mithochondrial membrane.
To explore the effect of altered transport rates on the kinetics of glutamate
labeling, metabolite exchange across the mitochondrial membrane was
observed with 13 C NMR spectroscopy in hearts oxidizing 2.5 mM [2- 13 C]
butyrate at normal (no lactate) or high cytosolic redox state (2.5 mM lactate).
High cytosolic redox state showed little effect on substrate utilization and TCA
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cycle activity. The TCA cycle flux was 9.7±0.5 gmoles/min/g dry weight with
butyrate only and 10.2±0.3 with butyrate plus lactate. However, lactate
induced a more than four-fold increase in the interconversion rate, from
3.1±0.2 gmoles/min/g dry weight to 14.3±2.0. These data indicate increased
metabolite transport across the mitochondrial membrane due to stimulated
malate-aspartate shuttle activity in response to elevated cytosolic redox state.
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Chapter 1
Introduction
"Organisms, composed of material which is characterized by the utmost
inconstancy and unsteadiness, have somehow learned the methods of maintaining
constancy and keeping steady in the presence of conditions which might reasonably be
expected to prove profoundly disturbing."
- Walter B. Cannon, "The Wisdom of the Body"
Myocardial performance in functioning heart is closely related to the
metabolic events in cardiac cells. Like any other organs, the heart consists of a
complex system of interactive proteins, energy-providing intermediates,
membranes, ions, and signal molecules, all of which are in a constant state of
flux. Heart muscle has retained its ability to adapt to environmental changes
by changing flux through metabolic pathways to maintain its state of
equilibrium. And the balance of energy production and utilization is
therefore achieved in support of contractile function. Only the most severe
environmental changes, such as those induced by an interruption of oxygen
supply, result in a collapse of energy production. Hence, it is important to
understand how the pathophysiological state of the myocardium is translated
into the cell organelle to coordinate the metabolic activity of the myocardium.
Substrate metabolism in the heart has been the subject of intense research
since the beginning of the century. A great deal of the detailed understanding
of metabolic pathways has come from studies on isolated enzymes and on
organelles. With the search for the relationship between several co-existent
pathways and their regulation in intact heart, progress in the understanding
of metabolic regulation has always been closely linked to advances in
biochemical and physiological methods. Among these exciting advances,
nuclear magnetic resonance (NMR) spectroscopy has rapidly become a
powerful tool in the study of cardiac metabolism, largely due to its non-
invasive nature and being chemically specific. These unique features allow
simultaneous assessment of metabolic and contractile functions in intact,
beating heart.
The work presented in this thesis aimed at developing new analysis
techniques in the evaluation and interpretation of data obtained from
dynamic carbon-13 (13C) NMR spectroscopic studies. A kinetic model was
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developed to facilitate the analysis of dynamic 13C NMR data. The model was
extensively tested by introducing various metabolic perturbations to the
chosen physiological model. Experimental methods, including the
acquisition and analysis of NMR data, the evaluation of physiological
function and metabolic states of the tissue, and the biochemical analysis of
tissue metabolism, were established. The work explored the potential of
using dynamic 13C NMR technique to investigate metabolic communications
between subcellular compartments.
Following this introduction, various experimental components of this
work are discussed in Chapter 2. Chapter 3 describes the construction of a
mathematical model and the optimization technique employed in kinetic
analysis. Some practical considerations in using this technique are also
discussed. The results derived from applying kinetic analysis to the
interpretation of NMR data are presented in Chapter 4. Furthermore, the
potential for using 13C NMR spectroscopic method to monitor metabolite
transport between subcellular compartments is explored in Chapter 5,
followed by a brief summary and the discussion of some future research
directions in Chapter 6.
1.1 Physiological Functions and Intermediary Metabolism
The heart converts chemical energy into mechanical energy to develop
pressure and to pump blood. The main purpose of cardiac metabolism is to
provide energy to support rhythmic contraction, ion transport, biosynthesis
and degradation. Like any other living organ, the immediate source of
chemical energy in myocardium is in the form of adenosine triphosphate
(ATP), a molecule with high energy bonds. The free energy in ATP is utilized
by the controlled hydrolysis of ATP to adenosine diphosphate (ADP) and
inorganic phosphate (Pi) by various adenosine-triphosphatases (ATPases) in
the cytosol to perform work. The tissue content of ATP is normally around
20 gmoles/g dry weight, and the heart muscle utilizes 1400 gmoles
ATP/min/g dry weight (25). Thus, under steady state conditions, ATP has to
be continuously regenerated from its breakdown products, ADP and Pi.
Because the heart is at constant rhythmic contraction, the rate of ATP
turnover in the heart is far greater than in other organs of the mammalian
body. It was estimated that a human heart produces 35 kg of ATP in the
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course of 24 hours, more than 100 times its own weight and more than 10,000
times the amount of ATP stored in the heart (122).
Figure 1.1 Stages of cardiac energy metabolism. The first stage comprises all pathways
leading to acetyl-CoA; the second stage is the oxidation of acetyl-CoA in the TCA
cycle; the third stage consists of the flow of electrons down the respiratory chain
leading to release of free energy.
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The major source of ATP in myocardium is oxidative phosphorylation of
ADP coupled to the electron transport chain, phosphorylation of ADP in
glycolysis and the tricarboxylic acid (TCA) cycle, and by the action of creatine
kinase (46, 92). Quantitatively, oxidative phosphorylation is the main source
of ATP. Oxidative phosphorylation of ADP depends on the production of
electron rich reducing equivalents, i.e. flavin adenine dinucleotide (FADH2)
and nicotinamide adenine dinucleotide (NADH), and the transfer of electrons
along the electron transport chain. Reducing equivalents are produced in the
process of substrate catabolism to acetyl-CoA and subsequent oxidation of the
acetyl group in the tricarboxylic acid (TCA) cycle. Cardiac metabolism can,
therefore, be grouped into three stages: the formation of acetyl-CoA, the TCA
cycle, and the oxidative phosphorylation (Figure 1.1).
The end-product of stage 1 is the formation of acetyl-CoA that prepares
carbons for oxidation. The synthesis of acetyl-CoA is irreversible and is under
close control by hormonal, cation and substrate level regulation. Stage 2
consists of the oxidation of acetyl-CoA to CO 2 and the production of reducing
equivalents in the TCA cycle. In stage 3, further oxidation of NADH and
FADH 2 generated in the TCA cycle is accomplished by the transfer of electrons
down the electron transport chain, or the respiratory chain, generating an
electrochemical gradient that provides the free energy for ATP synthesis.
1.1.1 Fatty Acid Metabolism
Under aerobic conditions, mammalian heart is capable of deriving energy
from a variety of fuel sources such as fatty acids, glucose, lactate, ketone
bodies, and even certain amino acids (25). Among these, free fatty acids are
the preferred substrate (115). The biochemical strategy of fatty acid oxidation
was discovered by Franz Knoop in 1904 (50), long before the advent of
modern biochemical techniques involving enzyme purification or the use of
radioactive tracers. However, it was not until after 1950, following the
discovery of coenzyme A, that the enzymes of fatty acid oxidation were
isolated and their reaction mechanisms elucidated (120).
The complete oxidation of fatty acid requires first its activation to acyl-CoA
in the extramitochondrial compartment. This activation process is an ATP-
dependent reaction and is catalyzed by a family of at least three chain length
specific acyl-CoA synthetase.
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Fatty acid + ATP + HSCoA acyl-CoAsthete Acyl-CoA + AMP + PPi
The acyl-CoA is then transported into the mitochondrial matrix to be
oxidized (11). Since acyl-CoA molecules cannot penetrate the inner
mitochondrial membrane, the transfer of acyl-CoA into mitochondria
requires the participation of two membrane-bound enzymes called carnitine
acyltransferases (Figure 1.2). Carnitine acyltransferase I, located on the
cytosolic side of the mitochondrial membrane, transfers acyl-CoA to acyl-
carnitine. Acyl-carnitine is then transported into mitochondria by carnitine
carrier. Once inside the mitochondrial matrix, the acyl-carnitine is
reconverted to carnitine and acyl-CoA by carnitine acyltransferase II located
on the inner side of the mitochondrial membrane. Carnitine formed by the
latter reaction is then transported back into the cytosol where it exchanges for
more acyl-CoA. The rate of this transport process is determined mainly by the
concentrations of the reactants.
Inner
Cytosol mitochondrial Matrix
membrane
rarnitne
arnitine
ran=erase I
Acvl-carn
Carnitine
carnitine
transferase
er lcrniti
Figure 1.2 The transport of fatty acids into the mitochondrion. Fatty acid is first
activated to acyl-CoA in the cytosol. The acyl group of a cytosolic acyl-CoA is
transferred to carnitine thereby releasing the CoA to its cytosolic pool. The resulting
acyl-carnitine is transported into the mitochondrial matrix by the transport system.
The acyl group is then transferred back to a CoA molecule from the mitochondrial pool.
And the product carnitine is returned to the cytosol.
Once inside the mitochondria, acyl-CoA enters the TCA cycle as acetyl-
CoA. Acetyl-CoA is generated by the stepwise breakdown of long-chain fatty
acyl chains by a series of reactions. This process is called 13-oxidation, it
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involves four reactions that are catalyzed by different enzymes and require
several cofactors including CoA, FAD, and NAD + (Figure 1.3).
CH 3- (CH 2)n - CH2 -
O
II
CH2 - C - S -CoA Fatty acyl-CoA
acyl-CoA
dehydrogenase
H O
I II
CH 3- (CH 2)n- C = C - S - CoAI
H
H20
H O
I II
C- CH 2- C -S -CoA
OH
trans-A2-Enoyl-CoA
3-L-Hydroxyacyl-CoA
NADI
3-L-hydroxyacyl-CoA
dehydrogenase
NADH+H +
O O
II II
CH3 - (CH2)n - C - CH2 - C - S - CoA
fl-ketoacyl-CoA
thiolase
f-Ketoacyl-CoA
rCoASH
0 0
II II
CH3 - (CH2)n - C - S -CoA + CH 3 - C - S - CoA
Fatty acyl-CoA
(2 C atomes shorter)
Figure 1.3 The P-oxidation pathway of fatty acyl-CoA. Each turn of P-oxidation
involves four reactions, two of oxidation, one of hydration, and one of thiolysis. Each
turn shortens fatty acyl-CoA by two carbons by releasing one acetyl-CoA molecule. The
shortened acyl-CoA is then able to reenter another turn of P-oxidation. This process
continues until the fatty acyl-CoA is converted entirely to acetyl-CoA.
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The four sequential reactions in P-oxidation are very tightly coupled to
each other, so that the concentrations of the fatty acyl intermediates are
normally very low. The energy that becomes available in the two oxidative
steps of P-oxidation is trapped in reduced FADH 2 and NADH; these generate
ATP when they are subsequently oxidized in the electron transport chain
coupled to oxidative phosphorylation.
Regulation of (-oxidation in intact cells occur through the availability of
acyl-CoA and oxidized NAD+ and FAD (12). The rate of (-oxidation is geared
to flux through the TCA cycle and to the rate of oxidative phosphorylation. A
high NADH/NAD+ ratio inhibits the 3-L-hydroxyacyl-CoA dehydrogenase.
The presence of succinate inhibits the overall rate of (-oxidation in isolated
mitochondria by competing for FAD (86). Under normal conditions, the rate
of (-oxidation is much faster than that of fatty acid activation, so that the
overall rate of fatty acid oxidation in the well-oxygenated heart is normally
governed by the reactions responsible for fatty acid entry into the
mitochondria.
The metabolism of short-chain fatty acids (C4-10) is different from the long-
chain fatty acids in that their activation to acyl-CoA by specific acyl-CoA
synthetases takes place in the mitochondrial matrix. The short-chain fatty
acids therefore bypass the extramitochondrial processes and the carnitine-
dependent transfer mechanism (13, 36). Their metabolism consequently
appears to be subject to little regulation.
1.1.2 The Tricarboxylic Acid Cycle and Its Regulation
The tricarboxylic acid cycle (TCA cycle), also known as the citric acid cycle
or the Krebs cycle, accounts for the major portion of carbohydrate, fatty acid,
and amino acid oxidation and generates numerous biosynthetic precursors.
Discovered by Hans Krebs in 1937 (53), the discovery of the TCA cycle is
ranked as one of the most important classical achievements in metabolic
chemistry.
Reactions of the TCA cycle are shown in Figure 1.4. Most of the enzymes
for the TCA cycle are soluble enzymes in the mitochondrial matrix (38). The
major role of the TCA cycle in heart is to accomplish the oxidation of the
acetyl group of acetyl-CoA to CO 2 and water. Reducing equivalents are
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thereby produced in the mitochondria, their reoxidation by the enzymes of
the electron transport chain being coupled to ATP synthesis. A small amount
of ATP is also generate by transferring the high energy bond from guanosine
triphosphate (GTP) to ADP. In summary, one turn of the TCA cycle results in
the following chemical transformation:
1. One acetyl group is oxidized to two molecules of C0 2;
2. Three molecules of NAD + are reduced to NADH;
3. One molecule of FAD is reduced to FADH 2;
4. One high-energy phosphate group is produced as GTP.
Acetyl-CoA
citrate
Oxaloacetate synthase Citrate
NAD+
Ite
tdrogenase
arase
aconitase
Isocitrate
isocitrate NAD+
dehydrogenase
CO2  NADH+H +
4•T 
- I t 
- rFumarate
succinyl-CoA
synthetase
GTP
tetoglutarate NAD+
hydrogenase
CO2
NADH+H+
uccinyl-CoA
GDP+Pi
Figure 1.4 The TCA cycle pathway. Condensation of the two-carbon acetyl group from
acetyl-CoA with the four-carbon oxaloacetate yields a six-carbon citrate. The latter,
after isomerization to isocitrate, is oxidized and decarboxylated. The resulting five-
carbon a-ketoglutarate is oxidized and decarboxylated in a reaction that yields
succinyl-CoA. Oxaloacetate is regenerated after succinyl-CoA undergoes two steps of
oxidation and one step of hydration.
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Acetyl groups are thereby completely oxidized to CO 2 with the following
stoichiometry:
Acetyl-CoA + 3NAD+ + FAD + GDP + Pi --
2CO 2 + CoA + 3NADH + FADH2 + GTP
Regulation of the TCA cycle is associated with feedback interactions that
allow flux through the cycle to keep pace with the energy expenditure by the
heart. Establishing the rate-determining steps of the TCA cycle is difficult
because most of the cycle's metabolites are present in both mitochondria and
cytosol and we do not know their distribution between these two
compartments. Many of the conclusions have been drawn either from
studies of isolated mitochondria or by making the assumption that
metabolites distribute equally between the two compartments.
Three enzymes are likely to function far from equilibrium under
physiological condition and act as the regulatory enzymes of the TCA cycle
(135): citrate synthase, isocitrate dehydrogenase, and a-ketoglutarate
dehydrogenase. These enzymes are controlled almost entirely in three simple
ways: substrate availability, production inhibition, and competitive feedback
inhibition by intermediates further along the cycle.
Citrate synthase, which catalyzes the condensation of acetyl-CoA and
oxaloacetate, is one of the earliest sites to be proposed as a key point of
regulation (3, 57). Acetyl-CoA and oxaloacetate are present in mitochondria at
concentrations that do not saturate citrate synthase (124). The metabolic flux
through the enzyme therefore varies with substrate concentration and is
subject to control by substrate availability. In addition, citrate synthase is
inhibited by an allosteric effect of ATP.
Isocitrate dehydrogenase controls the production of a-ketoglutarate from
isocitrate. It is strongly inhibited by NADH. In vitro studies also suggest that
ADP acts as an allosteric activator of isocitrate dehydrogenase by decreasing its
apparent Km for isocitrate. ATP, on the other hand, inhibits this enzyme.
Thus, a fall in the high-energy phosphate levels within the cell accelerates the
TCA cycle. However, whether high-energy phosphate levels also act as
regulatory factors in intact heart is not clear, as studies using nondestructive
phosphorus-31 nuclear magnetic resonance techniques demonstrated in vivo
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that there is little correlation between workload and ATP, ADP or Pi levels
(4).
a-Ketoglutarate dehydrogenase is also strongly inhibited by its product,
NADH and succinyl-CoA. Succinyl-CoA production is inhibited in the
anaerobic heart because of NADH. Succinyl-CoA also competes with acetyl-
CoA in the citrate synthase reaction. In addition, Ca 2+ activates both isocitrate
dehydrogenase and a-ketoglutarate dehydrogenase.
At metabolic steady state, all the TCA cycle intermediates are at constant
levels. Changes in workload or substrate utilization can induce a change in
these metabolite concentrations. However, since the entry of two carbon
acetyl group into the TCA cycle is balanced by the release of two CO2
molecules, other reactions must be responsible for the regulation of TCA cycle
intermediates. Reactions that replenish the TCA cycle intermediates are
called anaplerotic reactions, and reactions contributing to net efflux of carbon
from the TCA cycle are called cataplerotic reactions (70, 95). Besides regulating
intermediate pool sizes of the TCA cycle, these two types of reactions are also
involved in both the feedback control of TCA cycle flux and the metabolic
communication between the mitochondrial and cytosolic compartments (52).
1.1.3 Electron Transport and Oxidative Phosphorylation
Oxidative phosphorylation provides quantitatively the most important
mechanism by which energy derived from fuel molecules can be transferred
to ATP. The overall reaction of oxidative phosphorylation can be viewed as
the transfer of hydrogen from NADH and FADH 2 to oxygen.
1NADH + H + + -02 - NAD + + H 2 0 + 218 kJ/mol2
and
1
FADH 2 + -02 <-- FAD + H2 0 + 157 kJ/mol2
The standard free energy required to synthesize 1 mole of ATP from ADP
and Pi is 30.5 kJ/mol. The standard free energy of oxidation of NADH, when
coupled to ATP synthesis, is therefore sufficient to drive the formation of
several moles of ATP. This coupling is achieved by an electron transport
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chain in which electrons are passed through three protein complexes
containing redox centers, or cytochromes, with progressively greater electron
affinity. The free energy in NADH and FADH 2 is harnessed to create an
electrochemical gradient by the movement of protons out of the
mitochondria.
The proton electrochemical gradient across the mitochondrial membrane
is used in the synthesis of ATP by proton-translocating ATP synthase, or FoF 1-
ATPase, which projects from the surface of the inner mitochondrial
membrane into the matrix. Transduction of the electrochemical energy of the
proton gradient into the chemical bond energy of ATP occurs when proton
translocation energizes ATP synthase, which is followed by a subsequent step
in which this energy is transferred to a high-energy bond between ADP and
Pi. In this way, the large overall free energy change in NADH and FADH2 is
broken up into three smaller packets, each of which is coupled with ATP
synthesis. Oxidation of one NADH therefore results in the synthesis of three
ATPs. Oxidation of FADH2, whose entrance into the electron-transport chain
is regulated by a fourth protein complex, is similarly coupled to the synthesis
of two ATPs. Therefore, when the oxidation of acetyl group in the TCA cycle
is coupled to oxidative phosphorylation, a total of 12 ATPs are generated for
the oxidation of one acetyl molecule, with the consumption of two oxygen
molecules.
1.2 Intracellular Compartmentation and Metabolic Communication
between Intracellular Compartments
Like any other eukaryotic cells, cardiac cells contain extensive internal
membranes that define a collection of highly organized, subcellular structures
called organelles, each with a specialized function. Among these numerous
organelles, mitochondria, equipped with the key enzymes of oxidative
metabolism, are the sites of energy production. The primary role of
mitochondria in the myocardium is to supply the cardiac cells with ATP for
contraction and for the maintenance of ion homeostasis, protein synthesis,
and other important cellular functions. Since the energy requirement is
much higher in myocardium than in any other tissues due to constant
rhythmic contraction, mitochondria are quite abundant in cardiac cells (83, 99,
135). It has been estimated that the total mitochondrial content in cardiac
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cells is close to 250 mg/g dry tissue weight, and mitochondrial protein is 40%
of the total noncollagenous protein of cardiac tissue (44).
Electron microscopic studies reveals that mitochondrion has two
membranes: a smooth outer membrane and a highly folded inner membrane.
Thus the mitochondrion contains two compartments, the inner membrane
space and the internal matrix space. The enzymes that catalyze the reactions
in oxidative metabolism are located in either the gel-like matrix or the inner
mitochondrial membrane. The inner membrane space provides a controlled
compartment for some metabolic enzymes such as creatine kinase and
nucleoside diphosphate kinase (83).
The outer membrane provides structural support of the organelle. It is
relatively porous and does not limit permeability of molecules up to 10,000
daltons (83). The inner membrane is the most active compartment of the
mitochondria. It is selectively permeable and thus controls the transport of
essential components into the mitochondria. This function is accomplished
by various carrier systems or translocases such as the adenine nucleotide
translocase, the phosphate carrier, the calcium carrier and the substrate
transporters, the mono- and dicarboxylate carriers and the carnitine-
acylcarnitine translocase. These carriers or translocases are essential for the
function of the mitochondrion, because all the enzymatic reactions related to
ATP synthesis take place in either the inner membrane or in the matrix space.
Glycolysis takes place in the cytosol and also generates reducing
equivalents. However, while the NADH formed in mitochondria has direct
access to the enzymes of oxidative phosphorylation, NADH produced in the
cytosol must be transported into the mitochondria before it can be reoxidized,
and the reoxidized NAD+ must be returned to the cytosol since it is essential
for glycolysis. Because the inner mitochondrial membrane is not permeable
to this coenzyme, the exchange of NADH produced in the cytosol for NAD +
produced in the mitochondria cannot take place by simple diffusion. In
myocardium, transfer of NADH into the mitochondria in exchange for NAD+
is accomplished by a special membrane transport system, the malate-aspartate
shuttle (105).
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Figure 1.6 The malate-aspartate shuttle. The operation of the shuttle involves
oxidation-reduction and transamination reactions in both cytosolic space and
mitochondrial matrix, accompanied by the efflux of aspartate and a-ketoglutarate and
the influx of glutamate and aspartate. MDH: malate dehydrogenase; GOT: glutamate-
oxaloacetate transaminase.
The malate-aspartate shuttle involves not only oxidation and reduction
reactions, but also transaminations (Figure 1.6). The reduced NADH formed
in the cytosol is oxidized to NAD + by the coupled reduction of oxaloacetate to
malate catalyzed by malate dehydrogenase (MDH). Malate is then transported
into the mitochondria by the malate/a-ketoglutarate carrier. Once inside the
mitochondria, malate is reoxidized to oxaloacetate. In the mean time, NADH
is regenerated. The net effect of this reaction is the same as if NADH from the
cytosol were exchanged for NAD + in the mitochondria.
To complete the malate-aspartate cycle, additional reactions are needed to
return the excess oxaloacetate from the mitochondria to the cytosol, since the
inner mitochondrial membrane is impermeable to oxaloacetate. The
glutamate-oxaloacetate transaminase (GOT) first converts mitochondrial
oxaloacetate to aspartate with concomitant conversion of mitochondrial
glutamate to a-ketoglutarate. Aspartate is then transported to the cytosol by
the glutamate/aspartate carrier in exchange for cytosolic glutamate. Cytosolic
aspartate is then converted back to oxaloacetate in conjunction with the
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conversion of ca-ketoglutarate to glutamate, thereby restoring the initial level
of oxaloacetate in the cytosol.
Two carriers are involved in the malate-aspartate shuttle: the
electroneutral malate /a-ketoglutarate carrier and the electrogenic
glutamate/aspartate carrier. The malate/a-ketoglutarate carrier catalyzes the
exchange of malate and a-ketoglutarate. As there is no net movement of
electrical charge across the mitochondrial membrane, the exchange of malate
for a-ketoglutarate can occur in both directions, yet the affinity for intra- and
extra-mitochondrial substrates are different (117). On the contrary, besides the
exchange of glutamate and aspartate, a proton is also transported with
glutamate in glutamate/aspartate carrier mediated transport (58). Since there
is a large negative potential across the mitochondrial membrane under
physiological conditions, entry of glutamate and efflux of aspartate from the
mitochondria is virtually a unidirectional process.
In addition to regulating the transport of reducing equivalents across the
inner mitochondrial membrane, the malate-aspartate shuttle also provides
means for metabolic control and the integration of the many individual
catalytic reactions that are responsible for energy production in the heart. It
influences the flux through the TCA cycle by modulating the concentrations
of oxaloacetate and a-ketoglutarate within the mitochondria. Distribution of
other intermediates provides additional means of communication between
cytosolic and mitochondrial metabolism (61, 105, 137).
1.3 Tracing Metabolic Pathways by NMR Spectroscopic Methods
Since its discovery by Bloch and Purcell in 1946, nuclear magnetic
resonance (NMR) has evolved into a highly successful tool of physics,
chemistry, and biochemistry. In the last twenty years, NMR spectroscopy has
become a widely used technique for the evaluation of cardiac biochemistry,
function, and pathology (94). The value and role of NMR spectroscopy in
solving biochemical problems derives from its exquisitely detailed
informational content concerning the chemistry and physical environment
of the component being detected. Because of the non-invasive nature of
NMR spectroscopy, metabolic activities in intact organ system can be studied
in conjunction with physiological measurements (2, 9, 35, 40). Of particular
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interest is the information that can be obtained with phosphorus-31 (31P) and
carbon-13 (13C) NMR.
3 1P is by far the most commonly studied nucleus in cardiac NMR
spectroscopy. 31p isotope is present at 100% natural abundance and requires
no isotopic enrichment for measurement. 31P NMR allows measurement of
cellular levels of ATP, phosphocreatine (PCr), and inorganic phosphate (Pi) as
well as intracellular pH estimates (37). Furthermore, using magnetization
transfer techniques, unique information has been obtained concerning the
rate constants for physiologically important processes such as phosphate
exchange via creatine kinase in the intact heart (7, 8). Thus, 31P NMR
methods can directly investigate the mechanism whereby the myocardium
synthesizes, transfers, and uses the high-energy phosphate compounds for
contraction.
13C NMR spectroscopy is especially useful for studying metabolic
turnover, as well as the effects of drugs and hormones on such turnover.
Unlike 31p, 13C is present naturally at only 1.1% and is 1.6% as sensitive as 1H.
Thus, the application of 13C NMR requires the use of substrates enriched in
13C to obtain adequate spectral sensitivity. However, enriched compounds
are useful for determining the flux through a particular biochemical pathway
or for following substrate metabolism in general, because any observed signal
arises either from the exogenous label or from its metabolic products. This
capability provides useful experimental control in evaluating specific
metabolic pathways. Another major advantage of 13C NMR is that 13C
resonances display a much wider chemical shift range than 1H (~200 ppm
versus -10 ppm). This permits resolution of 13C resonances in molecules that
are structurally quite similar, whereas the corresponding 1H resonances may
overlap. Therefore, 13C NMR provides unique and detailed information
about tracer distribution in intermediary metabolites and allows more
comprehensive mathematical modeling of the metabolic processes.
An important early contribution in 13C NMR spectroscopy was the
analysis of steady-state isotopomer distribution in certain metabolites,
especially glutamate (69, 74-77, 110, 111). From high resolution 13C NMR
spectra of tissue extracts taken at steady-state conditions, the multiplet
structures in glutamate resonance signals due to 13C-13C coupling allowed the
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relative concentrations of the various isotopomers to be determined. The
analysis of such isotopomer distribution allowed the relative contribution of
various substrates to the overall TCA cycle flux, as well as relative anaplerotic
flux to be calculated. These approaches, however, are limited in that they do
not provide estimates of absolute metabolic fluxes. And the necessity for
tissue sampling due to the requirement for high resolution spectrum also has
limited its applications to in vivo studies.
Dynamic 13C NMR spectroscopy allows absolute metabolic flux along a
particular metabolic pathway to be estimated. As 13C-enriched substrate is
metabolized, 13C label is transferred to various metabolic intermediates. The
labeling pattern is dependent on the chemistry of the enzyme reactions, and
the rate of labeling is determined by flux through the pathway and the pool
sizes of the intermediates. From the 13C NMR spectra, resonances attributable
to specific carbon atoms of particular intermediates are identified by their
chemical shifts. The area of the resonance peak, when corrected for nuclear
Overhauser enhancement (NOE), is proportional to the 13C content of the
particular carbon site, and the fractional 13C enrichment can be calculated if
the intermediate pool size is known. The type of information obtained is
similar to that obtained by use of 14C isotopes, but with the advantages that
the metabolites of interest need not be isolated, purified, and chemically
degraded to obtain the fractional 13C enrichment at each position within a
molecule. More importantly, the 13C NMR technique permits data to be
obtained continuously and nondestructively while metabolism is in progress.
Hence, integrated biochemical and physiological response of the tissue to
external interventions may be explored.
Since its first application to cell suspensions in following metabolic routes
of exogenous 13C enriched substrates in 1972 (30), 13C NMR spectroscopy has
been applied to a wide range of biological systems including isolated cells (21,
22), perfused liver (20, 23) and heart (1, 18, 71, 112), and in vivo organs (34, 100,
116). It has generated widespread interest for application to laboratory
investigations of intact organs and in vivo animal models (16). The first
perfused heart study by 13C NMR (1) showed that it is possible to detect
enriched aspartate and glutamate signals and follow the time dependence of
13C incorporation into these pools in hearts supplied with [2- 13C] acetate.
Chance et al. measured the time dependence of 13C fractional enrichment at
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each carbon position in these same pools in freeze-clamped extracts of
perfused hearts and fit the data to a mathematical model of the TCA cycle to
obtain carbon flux information (17). Neurohr et al. (90) have demonstrated
the feasibility of detecting 13C-enriched glutamate signals from the heart of an
open-chested guinea pig during intravenous infusion of [2-13C] acetate. To
date, numerous studies have exploited this unique technique to quantify
several aspects of metabolism in intact heart at both normal (63, 65, 68, 100)
and diseased state (18, 67, 71, 72, 132).
1.4 Motivations and Objectives
A disadvantage of NMR spectroscopy is its low sensitivity. Hence, the
carbon resonance cannot be resolved above the base-line unless 13C level is
high. With present instrumentation, 13C resonances can only be detected in
intact tissues if their concentration exceeds a limit of about 0.5 mM. Since
most TCA cycle intermediates are normally present in tissues below this
concentration, and hence cannot be observed directly by NMR even with 13C
enrichment, current 13C NMR technique relies almost exclusively on the
observation of isotope incorporation into glutamate, a metabolite that is in
constant exchange with TCA cycle intermediates through transamination
with a-ketoglutarate. However, as glutamate itself is not a TCA cycle
intermediate, glutamate labeling remains an indirect indicator of 13C labeling
of the TCA cycle intermediates. And the influence of isotope exchange rate
between glutamate and a-ketoglutarate on isotope turnover within the
glutamate pool is not well characterized.
Many of the studies have drawn their conclusion based on the assumption
that a-ketoglutarate is in rapid exchange with glutamate (81, 82, 130, 132).
Until now, this assumption has not been tested in intact tissues, although
isolated enzyme measurements of liver glutamate-oxaloacetate transaminase
(GOT), the enzyme that catalyzes this reaction, does show that the enzyme has
a large Vmax value (32, 33). Another frequently overlooked factor is that since
about 90% of the glutamate is located in the cytosol (55), the labeling of
glutamate also involves the transport of metabolites across the mitochondrial
membrane through carrier mediated transporters. And the transport of
metabolites is inevitably influenced by mitochondrial membrane potential
and the redox-dependent malate-aspartate shuttle (105, 106). Whether this
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transport is fast enough to be negligible in studies of intact tissues is even less
well established. Thus, the evolution of presteady state 13C NMR spectra is
unlikely to be determined solely by TCA cycle activity and may, in fact, be
dominated by metabolic communication between subcellular compartments.
In an effort to further the application of dynamic 13C NMR spectroscopy,
this work was aimed at targeting the above stated problems in presteady-state
13C NMR observation of tissue metabolism. It was based on the hypothesis
that dynamic observation of glutamate labeling is an index of the TCA cycle
flux and can be used to ascertain rate limiting steps in metabolic pathway. In
order to approach a solution to this problem, a mathematical model
describing the kinetics of glutamate labeling was developed for the analysis
and comprehensive evaluation of acquired NMR data. The model allowed
absolute fluxes to be determined and rate-limiting steps in glutamate labeling
to be identified through kinetic analysis of dynamic NMR data. The model
was applied to evaluate variations in 13C kinetics through manipulation of
the TCA cycle flux by either workload or metabolic regulation, and the
contribution of both the TCA cycle flux and the interconversion rate between
a-ketoglutarate and glutamate to 13C turnover in glutamate was compared.
Finally, the potential of using dynamic 13C NMR technique to observe other
metabolic processes was also explored.
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Chapter 2
Experimental Design
Described in this chapter are several experimental techniques used in this
study, including preparation of physiological model, enzymatic assays for the
analysis of tissue metabolites, and various NMR techniques. These
experiments provide data and information necessary in the analysis of
dynamic 13C NMR data. The kinetic analysis method is discussed in a
separate chapter (Chapter 3).
2.1 Physiological Model - Isolated Rabbit Heart
Isolated heart models are used to study myocardial metabolism without
the complications of neurogenic input, plasma-borne hormones, and the
metabolic activities of other organ systems. In well-oxygenated preparations,
ventricular performance is stable for periods in excess of three hours with
only slightly deterioration (87). In addition, isolated heart preparation allows
frequent perfusate sampling during the time course of perfusion.
Among the available perfusion techniques, the Langendorff perfusion
technique has become a widely used technique, particularly in conjunction
with nuclear magnetic resonance spectroscopy (72, 114). First devised by Oscar
Langendorff (54), the Langendorff perfusion refers to a preparation in which
blood or any other oxygenated and substrate containing fluid appropriate to
maintain cardiac activity was forced towards the heart through a cannula
inserted into the ascending aorta. After passing through the coronary
vascular system the perfusate flows out of the coronary sinus and the opened
right atrium. Since the perfusate is supplied to the heart through the
physiological ejection path, this technique is also referred to as retrograde
perfusion technique. Originally, the cardiac ventricle was beating empty
throughout the experiment. Hence, the heart was said to perform no defined
work. By inserting a balloon catheter into the left ventricle, the heart can also
perform isovolumic contraction. Unless special efforts are made to drain the
left ventricle, intraventricular pressure increases to levels slightly above the
perfusion pressure with each beat, due to a limited degree of ventricular
filling, arising either from the Thebesian circulation or from incompetence of
the aortic valve due to use of low viscosity perfusate.
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The isovolumic Langendorff perfused heart model is not an ejecting heart
preparation and as such "ejecting" heart model has been employed in the
study of cardiac physiology. However, the Langendorff perfused heart model
is frequently used in the study of both cardiac metabolism and mechanics. It
has been shown that the bioenergetics and mechanics of ejecting and
isovolumic perfused hearts are indistinguishable (107). One of the
limitations of the typical "ejecting" heart model is that it is potentially
unstable since perfusion of the coronary arteries is dependent on the
contractile activity of the heart. Therefore, it is more difficult to maintain the
heart at stable function due to experimental variations. In contrast, with the
isovolumic Langendorff model coronary perfusion pressure is constant,
regardless of contractile activity. Thus, the Langendorff perfused heart model
is generally accepted for assessing the mechanics, coronary flow, and
metabolism of the mammalian heart. It is a stable, highly reproducible, low
work preparation (29, 138). Therefore, Langendorff perfused rabbit hearts
were used in this study in order to have precise control over substrate
availability and workload.
Since aerobic metabolism generates most of the ATP for myocyte
contraction, myocardial oxygen consumption is coupled closely to myocardial
energy production and mechanical work in the normal heart (85, 88). Oxygen
consumption can therefore be used as an index of myocardial metabolic rate.
Myocardial oxygen consumption (MVO 2) is calculated by following equation
(85):
MVO 2 = (Solubility of 02 at 37°C) (coronary flow) ApO 2(weight of the heart)
here ApO2 is the arterio-venous 02 difference in mmHg, it can be calculated
from the difference in oxygen content of perfusion medium and coronary
effluent. The solubility of oxygen in perfusate at 370C and atmospheric
pressure is about 0.0016 gmoles/ml/mmHg. If the coronary flow rate is
expressed in ml/min, and the heart weight in grams of dry tissue, this will
give MVO2 in gmoles 02/min/g dry tissue weight.
Contractile function, on the other hand, is frequently assessed by rate-
pressure-product (RPP) which is defined as the product of heart rate (HR) and
left ventricular developed pressure (LVDP), i.e. RPP = HR x LVDP (48). If
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heart rate and left ventricular developed pressure are expressed in beats/min
and mmHg respectively, rate-pressure-product has the unit of
beats.mmHg/min, or simply mmHg/min. Numerous studies have
characterized the relationship between myocardial oxygen consumption and
cardiac workload in isolated heart (8, 51, 66, 85, 131). A linear relation exists
between oxygen consumption and rate-pressure product over a wide range of
cardiac work in several heart preparations (8, 66, 89). The slope of the
relationship, or the ratio of oxygen consumption to rate-pressure-product,
may be considered to represent an index of the heart's aerobic metabolic
efficiency.
Dutch belted rabbits weighing between 550 and 700 g have been used. The
animals were heparinized (1,000 units) and anesthetized with sodium
pentobarbital (100 mg/kg, intraperitoneal injection). The abdominal cavity
was opened by making a transverse incision just below the rib cage. The
diaphragm was transected, and lateral incisions were made along both sides of
the rib cage. Heart was then raised and excised. Immediately upon excision,
the heart was immersed in a solution containing 20 mM KC1 and 120 mM
NaCl for cardioplegia at O'C. During cardioplegia, the pericardium and excess
fat was cut from the heart to permit cannulation. The aorta was then
cannulated for retrograde perfusion at 100 cm hydrostatic pressure with a
modified Krebs-Henseleit buffer. The buffer contained 116 mM NaC1, 4 mM
KC1, 1.5 mM CaC12, 1.2 mM MgSO4, 1.2 mM NaH2PO 4, and 25 mM NaHCO3.
Adequate oxygen delivery was achieved by equilibrating the buffer with a 95%
02- 5% CO2 gas mixture. The buffer has a physiological pH value of 7.4 and
was kept at constant temperature of 370C.
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Figure 2.1 Schematic diagram of the perfusion system. The aorta is cannulated so that
the perfusate flows retrogradely down the aorta and directly into the coronary
arteries. A balloon placed through the left atrium into the left ventricle enables
measurement of left ventricular pressure.
A schematic diagram of the perfusion system is shown in Figure 2.1.
Isolated perfused hearts were placed within a sample tube in a 20 mm
broadband NMR probe (Bruker Instruments). The perfusion column
together with the NMR probe was situated in a vertical-bore superconducting
NMR magnet operating at a field strength of 9.4-tesla (Bruker Instruments).
Temperature of the hearts was continuously maintained at 37°C by warm air
flow controlled at the NMR system console. A latex balloon was placed in the
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left ventricle to allow the heart perform isovolumic contraction. The balloon
was inflated with water to create a diastolic pressure of 5-10 mmHg and was
connected to a pressure transducer line and physiograph (Gould, Inc.,
Cleveland, OH). Left ventricular developed pressure and heart rate were
continually monitored and recorded with this intraventricular balloon.
Coronary flow rate was also measured at different stages of perfusion. Oxygen
content of both perfusion medium in the supply line and coronary effluent
collected from the pulmonary artery was measured using a blood-gas analyzer
(Instrumentation Laboratory, Lexington, MA).
2.2 Experimental Protocol
During initial preparation, hearts were perfused with buffer containing 5
mM glucose (Reservoir 1 in Figure 2.2). Exogenous substrates were added to
the buffer after the heart was placed inside the magnet and the magnetic field
was shimmed for optimal homogeneity. Before each protocol, a start-point
31p spectrum was acquired to confirm the viability and metabolic stability of
the preparation. At the beginning of each protocol, hearts were perfused with
unlabeled substrate from a second reservoir for metabolic equilibrium, i.e.
steady-state metabolic fluxes and constant metabolite concentrations.
Although some investigators have reported that metabolite levels may
stabilize in a period of 3 to 5 minutes (137), all the hearts were perfused with
unlabeled substrate for 10 minutes to ensure that metabolic equilibrium was
established (98). During this period, a natural abundance 13C spectrum was
acquired. The substrate supply was then switched to the corresponding 13C
labeled substrate in the third reservoir. Sequential 13C spectra were then
acquired with time resolution of 1 to 2.5 minute until steady-state enrichment
was reached. Depending on the substrate and workload, it took
approximately 30 to 70 minutes for the heart to reach isotopic steady-state
enrichment. At the end of each protocol, an end-point 31P spectrum was
acquired for the final energetic state of the heart. After the perfusion column
was taken out from the magnet, the heart was freeze clamped in liquid
nitrogen and weighed. The freeze-clamped tissue was reserved for
biochemical assays and high resolution 13C NMR analysis. This protocol is
summarized in Figure 2.2.
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Figure 2.2. Perfusion protocol. Preparation is followed by a 10 minute period of
equilibration with unlabeled substrate. At the end of data acquisition, heart was
freeze clamped for in vitro analysis.
2.3 Tissue Biochemistry
Acid extracts were obtained from freeze-clamped ventricular muscle of
hearts perfused in the magnet. Approximately 2 ml/g tissue weight of 7%
perchloric acid (HC10 4) was added to the frozen tissue. The tissue was ground
to powder in liquid nitrogen and the homogenate was defrosted at 00 C. The
precipitated protein was centrifuged away. The acidic supernatant was then
neutralized to pH 6.5 ~ 7.0 with KOH and recentrifuged to remove the
precipitated KC10 4. Part of the tissue extract was reserved for biochemical
analysis, the rest was lyophilized and reconstituted in 0.5 ml deuterium oxide
(D20). High-resolution 1H and 13C spectra of reconstituted extract material
were obtained.
Glutamate, a-ketoglutarate, aspartate, and citrate contents in myocardium
were determined by spectrophotometric or fluorometric techniques (5, 136).
The basic principles for these assays are described below, with detailed
description of the assay systems included in Appendix A.
The measurements of all four metabolites have used coupled reactions in
which the substance to be determined is first transformed by the auxiliary
reaction, while an indicator reaction that reacts stoichiometrically with the
substance to be analyzed in the auxiliary reaction is used for actual
measurement. Especially in the measurement of x-ketoglutarate, aspartate,
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and citrate, the reaction catalyzed by malate dehydrogenase (MDH, EC 1.1.1.37)
has been used as indicator reaction in all three assays. Malate dehydrogenase
catalyzes the following reaction with the equilibrium lies in favor of the
oxidation of NADH (Keq=3 6,000) (61)
Oxaloacetate + NADH + H+  MDH > L-Malate + NAD+
Therefore, with oxaloacetate in stoichiometric proportion to the
transformed substance to be determined in the auxiliary reaction, the
disappearance of NADH in the combined assay system, which can be
measured either fluorometrically or spectrophotometrically, is also
stoichiometrically proportional to the concentration of the substance to be
determined.
2.3.1 Glutamate Assay
Glutamate level was determined with glutamate dehydrogenase (GDH, EC
1.4.1.2) and diaphorase. Glutamate dehydrogenase catalyzes the oxidative
deamination of L-glutamate to ca-ketoglutarate and NH 4+.
L-Glutamate + NAD + + H 20 ( GDH > a-Ketoglutarate + NH4+ + NADH + H +
In the reaction catalyzed by diaphorase the NADH formed in the above
reaction converts iodonitro tetrazolium chloride (INT) to a formazan which
is measured in the visible range at 492 nm.
NADH + INT + H+  diaphorase > NAD + + Formazan
The equilibrium of glutamate dehydrogenase lies far on the side of L-
glutamate. However, by trapping the NADH formed with INT, the
equilibrium is displaced in favor of a-ketoglutarate
2.3.2 ca-Ketoglutarate Assay
a-Ketoglutarate content was measured by coupling glutamate-oxaloacetate
transaminase (GOT, EC 2.6.1.1) with malate dehydrogenase (MDH).
Glutamate-oxaloacetate transaminase catalyzes the transamination of L-
aspartate and a-ketoglutarate to oxaloacetate and L-glutamate.
a-Ketoglutarate + L-Aspartate < GOT > L-Glutamate + Oxaloacetate
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With an excess of L-aspartate, when oxaloacetate is reduced to malate with
malate dehydrogenase and NADH, the disappearance of NADH in the
combined assay system is stoichiometrically proportional to the concentration
of a-ketoglutarate.
a-Ketoglutarate + L-Aspartate + NADH + H+  GOT,MDH
L-Glutamate + Malate + NAD+
2.3.3 Aspartate Assay
Aspartate concentration was also measured by coupling glutamate-
oxaloacetate transaminase with malate dehydrogenase. The assay system is
similar to that described above for the a-ketoglutarate assay, with the
exception that excess a-ketoglutarate is used in place of aspartate.
2.3.4 Citrate Assay
Citrate content was determined with citrate lyase (CL, EC 4.1.3.6) and
malate dehydrogenase (MDH). Citrate lyase, when activated by Mg + + ,
catalyzes the cleavage of citrate to oxaloacetate and acetate with the
equilibrium constant in favor of citrate synthesis.
Citrate 1 cL,M`'+ Oxaloacetate + Acetate
The reaction is coupled to malate dehydrogenase for the quantitative
removal of oxaloacetate, thereby pulling the overall reaction from left to
right.
Citrate + NADH + H +  CLMH > Malate + Acetate + NAD+
The accompanying decrease in fluorescence of NADH can then be
followed spectrophotometrically by the change in optical density at 340 nm.
2.4 NMR Techniques
All NMR data were collected on a Bruker 400MSL NMR spectrometer
interfaced to a 9.4-tesla, 89 cm vertical bore, superconducting magnet (Bruker
Instruments). Signal intensity of resonance peaks was determined for all
spectra by curve-fitting each resonance peak with a Lorentzian curve and
integrating the area under the fitted curve with NMR-dedicated software
(NMR1, Tripos Associates, Inc., St. Louis, MO).
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2.4.1 NMR of Isolated Perfused Hearts
31P and 13C spectra were obtained from isolated hearts perfused within a
broadband, 20 mm NMR probe equipped with a proton decoupling coil
(Bruker Instruments). Before each experiment, the magnetic field
homogeneity was optimized by shimming on proton signal from water to a
linewidth of 20 to 30 Hz.
Dynamic 13C spectra from intact hearts were acquired at 101 MHz with a
45" pulse angle, 2 second recycle time, and 80 ppm sweep width. Depending
on the substrate, the spectra were collected with a temporal resolution of 1 to
2.5 minutes (24 to 64 free induction decays). Bilevel broadband decoupling at
0.5 W (1.8 seconds) and 7.0 W (17 gsec) was applied to eliminate carbon-
proton coupling and induce Nuclear Overhauser Enhancement (NOE)
without sample heating. The free induction decay was acquired with 8K data
set. Changes in relative signal intensities due to Nuclear Overhauser
Enhancement or relaxation effect were negligible under these pulsing
conditions (69, 76). Natural abundance 13C signal was digitally subtracted, and
the raw signal was processed by exponential filtering with a line broadening
of 20 Hz to enhance the signal-to-noise ratio before being converted into
frequency domain by Fourier transformation. Peak assignments were
referenced to the known resonance of the exogenous, 13C enriched substrate
(2-carbon of acetate at 24.1 ppm, 2-carbon of butyrate at 40.2 ppm) and the well-
documented glutamate signals (4-carbon of glutamate at 34.4 ppm, 2-carbon of
glutamate at 55.7 ppm, and 3-carbon of glutamate at 27.9 ppm) (1, 17).
31p spectra were obtained at 161 MHz with a 45" pulse angle, 1.8 second
recycle time, and 35 ppm sweep width with 64 scans. The free induction decay
was acquired with 8K data set using quadrature phase detection. Raw 31p
signal was converted into frequency domain by Fourier transformation
following the application of exponential filtering (20 Hz line broadening).
The phosphocreatine (PCr) peak served as a reference at 0 ppm. Relative ATP
level was assessed from the intensity of the P3-phosphate peak at -16 ppm. The
pH was calculated from the chemical shift of inorganic phosphate (Pi) with
respect to PCr:
a -3.27pH= 6.75 + log( )
5.69 - a
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where a is the chemical shift of Pi (14, 93, 108).
3.4.2 High resolution NMR of tissue extracts
High resolution 1H and 13C spectra of tissue extracts reconstituted in 0.5 ml
D20 were acquired with a 5 mm 1H/1 3C probe (Bruker Instruments). Prior to
data acquisition, the magnetic field homogeneity was optimized by shimming
on proton signal from the sample to a linewidth of 0.8 to 1.2 Hz.
13C spectra were collected over 3000 or 6000 scans with broadband proton
decoupling. The samples were maintained at 25"C through out data
acquisition. Spectra were acquired using 45" excitation pulse and 1.8 second
recycle time. 32K points were collected over a 200 ppm sweep width using
quadrature phase detection. The free induction decay was zero filled to 64K to
improve spectral resolution. The signal was then processed by 1 Hz
exponential filtering followed by Fourier transformation. The multiplet
structure of glutamate due to 13C-13C spin-spin coupling in the isotopomers
was analyzed. The splitting due to the 13C-1 3C coupling is -34 Hz between
protonated carbons and -52 Hz between protonated and carboxyl carbons of
glutamate (20).
The relative concentrations of glutamate isotopomers are sensitive to the
various pathways for carbon flow into the TCA cycle. Therefore, high
resolution 13C NMR spectra can be interpreted in quantitative physiological
terms (74, 76). In the case of this study where all the 13C label enters the TCA
cycle through [2-13C] acetyl-CoA, the analysis of glutamate resonances allowed
the fraction of 2-carbon labeled acetyl-CoA entering the TCA cycle (F,) and the
ratio of anaplerotic flux to citrate synthase flux (y) to be calculated. Since all
the carbons enter the cycle through anaplerotic flux are unlabeled, the
equations relating F, and y to the multiplet structures of glutamate signals
can be simplified to
C2S = 2(y + 1)2 - 2F,(y + 1) -F + F2  (2.1)
2(y + 1)2
C2D12= FcoFe (2.2)
2(y + 1)2
C2D23= F(2+2y-Fc) (2.3)
2(y + 1)2
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C3S = FO(Fco + y) (2.4)
y+ 1
C3T = (2.5)
y+l
FC4D34 = F (2.6)2y+1
where
Fco = 1- Fe = Fraction of unlabeled acetyl-CoA entering the TCA cycle;
C2S = Area of singlet/C-2 resonance area;
C2D12 = Area of doublet due to C-1 coupling/C-2 resonance area;
C2D23 = Area of doublet due to C-3 coupling/C-2 resonance area;
C3S = Area of singlet/C-3 resonance area;
C3T = Area of triplet/C-3 resonance area;
C4D34 = Area of doublet due to C-3 coupling/C-4 resonance area.
The left sides of Equations (2.1) - (2.6) were obtained from in vitro 13C
NMR spectrum by peak integration. Fe and y were determined for each
experiment by least-square fitting of the right sides of Equations (2.1) - (2.6) to
the left sides. The fitting was performed using MATLAB (The MathWorks
Inc., Natick, MA). The MATLAB program for the evaluation of Fe and y is
included in Appendix B.
The amount of glutamate labeled at 4-carbon position was determined by
referencing the signal intensity from glutamate C4 resonance peak in each 13C
spectra to the 2 mM glucose C1-oc signal (24). Total 13C labeled glutamate at 4-
carbon position was then divided by total tissue concentration of glutamate
from enzymatic assay to obtain the fractional enrichment of glutamate at the
4-carbon position.
For hearts perfused with [3-13C] lactate, water suppressed 1H spectra were
also obtained to quantify the fraction of 13C enriched alanine. The spectra
were acquired using a 1331 pulse sequence (41, 42) with t=390 gsec so that the
maximum signal was centered between the resonances of methyl protons of
alanine (1.48 ppm) and lactate (1.33 ppm). 96 free induction decays were
acquired in 32K data set with 4.1 seconds recycle time and 10 ppm sweep
width.
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For both alanine and lactate, the protons bound to an unlabeled methyl
carbon appear as a 7 Hz doublet due to the proton-proton coupling of the
methyl proton to the vicinal proton. Those bound to a 13C are split into two
pairs of peaks that resonate on either side of the central doublet, with a J
coupling constant of 128 Hz (63). Therefore, the fraction of 13C labeled alanine
can be calculated as the ratio of the area of the two side peaks to the combined
area of the central and side peaks (24).
2.5 Statistical Analysis
All data are presented as mean ± standard deviation (Mean±SD).
Comparison of intragroup data sets was performed with the Student's paired,
two-tailed t test. Differences in mean values were considered statistically
significant at a probability level of less that 5% (p<0.05).
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Chapter 3
Kinetic Analysis of
Dynamic 13 C NMR Spectra
This chapter introduces the kinetic modeling technique developed for the
analysis of dynamic 13 C enrichment of glutamate. A brief review of the
existing methods in dynamic 13 C NMR spectroscopy will be followed by a
detailed description of the model, which is distinct from other previous
studies. The optimization technique used in kinetic analysis is also discussed.
Practical considerations are addressed at the end of this chapter.
3.1 Current Analytical Techniques of Dynamic 13C NMR Spectra
13C NMR spectra, whether obtained sequentially from the intact heart or
from tissue extracts, contain various sorts of information that require
mathematical treatment for a comprehensive evaluation. Several previous
studies have employed modeling schemes to explore TCA cycle flux and its
regulation (17, 19, 34, 81, 82, 101, 131). These methods are based largely on
previously described patterns of 14C incorporation in metabolites which were
determined by traditional, destructive biochemical methods (47, 49, 91, 98, 121,
129). An important early work, made by Chance et al., applied a kinetic model
to the analysis of 13C labeling within glutamate as detected in in vitro spectra
of tissue extracts at different time points (17). The modeling of 13C kinetic
data from rat heart perfused with [2- 13C] acetate and [3- 13 C] pyruvate lead to
the estimates of the TCA cycle flux and the aspartate and alanine
aminotransferase reaction rates. The model, however, requires the
simultaneous solution of nearly 200 differential equations and is
cumbersome to use since it uses a single compartment to represent each
individual 13C isotopomer. In addition, the results generated by that model
were not rigorously compared with other measures of TCA cycle flux over a
range of values, such as might be induced by varied physiological contractile
conditions. This model was recently expanded to include both glycolysis and
malate-aspartate shuttle, leading to an even more complicated model with
340 differential equations (19).
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Recognizing the limitations of such complicated model with large
numbers of equations to solve, Lewandowski used an empirical time constant
of glutamate 2-carbon/4-carbon (C2/C4) curve as an index of the TCA cycle
flux and demonstrated that under widely varying workloads, the
myocardium displayed unchanging fractional enrichments and glutamate
pool sizes, and yet very different time constant for C2/C4 curves (66).
Similarly, Weiss et al. have used an empirical flux parameter KT as and
index of the TCA cycle flux (131). KT is defined as
KT " 13C NMR - detected TCA metabolites (yumoles / g)
Fe x glutamate At5s (min)
where glutamate Atso is the time difference for the glutamate 4- and 2-carbons
to reach half of their steady-state enrichment levels. And the 13C NMR-
detected TCA metabolites include glutamate, aspartate, and citrate. Such an
approach is based on the assumption that the TCA cycle flux is inversely
proportional to the time difference between 13C appearance in the 4- and 2-
carbon positions of glutamate (glutamate At5so). However, this hypothesis
needs to be further validated with various substrates that can potentially
perturb the TCA cycle without significant changes in oxygen consumption
and workload. Furthermore, although KT has the unit of flux parameter, it is
not necessarily equal to the TCA cycle flux.
Robitaille et al. have proposed post-steady state analysis as an
complementary method to the pre-steady state method (101). The advantages
of using post-steady state analysis is that a closed form solution of the rate of
label washout from the 4-carbon of glutamate can be obtained. However, the
model is based on the assumption that the flux through a-ketoglutarate
dehydrogenase is much slower than the interconversion rate between a-
ketoglutarate and glutamate. This assumption yet needs to be further tested.
Mason et al. have developed a kinetic model for the analysis of glucose
metabolism in cerebral energy production (81, 82). 1H-observed/ 13C-edited
NMR spectroscopy technique was used in data acquisition to improve the
sensitivity of NMR measurements in brain in vivo (102, 103). However, by
using a 3-step procedure in data fitting, the use of Vgt, i.e. the rate of isotopic
flow into glutamate, made the intrinsic assumption without further
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validation that the exchange rate between a-ketoglutarate and glutamate was
fast.
The effort of developing new analytical techniques in this work was not to
improve any of the current existing models, but rather to identify potential
rate-limiting factors in 13C labeling of glutamate. As 1 3C spectra contain
various sorts of information, a comprehensive evaluation requires
mathematical treatment. Therefore, a significant portion of this work
comprised of the development of kinetic analysis method for the evaluation
of dynamic 13C NMR spectra. This method is presented in this chapter.
3.2 Compartment Model of the TCA Cycle
To establish the compartment model for kinetic analysis of the TCA cycle,
it is necessary to first examine the mechanism by which 13C label is
incorporated into the intermediary metabolite pools and detected by 13C NMR
(Figure 3.1).
Over the course of perfusion with 13 C-enriched substrate, incorporation of
label into the glutamate pool was detected by 13C NMR. The appearance of
resonance peaks that correspond to 1 3C enrichment at specific carbon
positions within the glutamate pool have been described in detail by others
(17, 45, 76). Detection of 13 C NMR signal from glutamate is based on the
relatively high concentration of intracellular glutamate that is in constant
exchange with the TCA cycle intermediates via transamination reaction with
a-ketoglutarate. Initial incorporation of label into the glutamate pool, from
the condensation of unlabeled oxaloacetate with [2-1 3 C] acetyl-CoA, occurs at
the 4-carbon position. The recycling of label through the TCA cycle places 13C
at either the 2- or 3-carbon of glutamate. The labeling at the 2- and 3-carbon of
glutamate is of equal probability due to the symmetry of succinate molecule.
This labeling scheme is shown in Figure 3.1. Although some investigators
have reported asymmetric labeling of malate in various mammalian tissues
perfused with 13 C labeled propionate (113), this phenomenon has not been
observed in NMR experiments involving functioning tissues oxidizing
substrates that enter the TCA cycle via acetyl-CoA (66, 131).
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Figure 3.1 Labeling scheme employed in dynamic 13C NMR spectroscopy. Exogenous
substrate enters the TCA cycle via [2-13C] acetyl-CoA. Initial sites of 13C labeling (*)
are at the 4-carbon position of citrate, a-ketoglutarate, and glutamate. Recycling of
'
3C within the TCA cycle results in the labeling of 2- and 3-carbons (t) with equal
probability.
The kinetic model for the presteady-state isotope turnover within key
metabolite pools is derived from the simplified metabolic compartment
model that includes major rate-limiting tricarboxylate pools such as citrate, CC-
ketoglutarate, malate, and oxaloacetate, as well as the major contributing
amino acid pools, i.e. glutamate and aspartate (Figure 3.2). This simplification
was justified by comparing the simulated results with that of a more
comprehensive model that also includes succinate and fumarate pool (139).
The model will be used to address 13C labeling within key metabolite pools.
Specifically, the presteady-state incorporation of 13C at 4- and 2-carbon
positions of glutamate and the fractional enrichment of 13C within several
key metabolite pools will be analyzed using the model. Analysis is carried out
at steady state metabolic flux and with constant intermediate pool sizes.
Because of the symmetry in 2- and 3-carbon labeling, the model only
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considers the labeling of 2-carbon while regarding the labeling of 3-carbon as
the same to that of 2-carbon. Citrate, a-ketoglutarate, and glutamate pools are
further divided into 2 subcompartments to represent 13C labeling at the 2- and
4-carbon positions of each intermediate.
Citrate a-Ketoglutarate Glutamate
Figure 3.2 Compartment model of the TCA cycle. Large boxes represent metabolite
pools of or related to the TCA cycle. Small boxes represent real mathematical
compartments of the model. Labeling of 3-carbon is the same as 2-carbon and is
therefore omitted. Mixing of label occurs after the a-ketoglutarate compartment.
Anaplerosis and cataplerosis occur at malate pool. Metabolite pools are, CIT: citrate;
aKG: a-ketoglutarate; GLU: glutamate; MAL: malate; OAA: oxaloacetate; ASP:
aspartate. Flux parameters are, VTCA: TCA cycle flux; F1: interconversion rate between
a-ketoglutarate and glutamate; F2: interconversion rate between aspartate and
oxaloacetate. C4 and C2 refer to the 4- and 2- carbon positions.
Effects of substrate utilization and anaplerosis are also accounted for by
incorporating data measured from high resolution 13C NMR as parameters in
the model. Incorporation of unlabeled intermediate through anaplerosis was
considered to enter the TCA cycle at malate while efflux of carbon mass
(cataplerosis) occurred through malic enzyme (52, 95, 104).
3.3 Mathematical Description of the Model
Analysis of metabolic activity was based on the observations of presteady
state 13C NMR spectra of glutamate reflecting the dynamic labeling pattern
described above. Kinetic equations describing presteady state labeling of 13C
within key metabolic compartments will be presented in detail in this section.
Let the steady state TCA cycle flux be VTr, the interconversion rate
between a-ketoglutarate and glutamate, oxaloacetate and aspartate be F, and
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F2 respectively. By the principle of mass conservation, the time rate of
change in 13C label in a compartment equals the difference of the amount of
13C label entering the compartment and the amount of 13C label leaving the
same compartment. While the amount of 13C label leaving the compartment
is the total flux leaving that compartment multiplied by the enrichment level
of that compartment, the amount of 13C label entering the compartment is
the flux entering that compartment multiplied by the enrichment level from
the upstream compartment. Therefore, the concentration history of the
metabolites can be characterized by a group of differential equations
incorporating both the TCA cycle flux and the interconversion rates between
metabolite pools.
* Citrate pool
d [CIT - C4]d [CIT - C4] = VTCA F- - VTCA• [CIT ] (3.1)dt [CIT]
d [CITC2 = V [OAA - C2]V [CIT - C2] (3.2)
dt [OAA] [ CIT]
* a-Ketoglutarate pool
d KG- C4] = V [CIT - C4] [aKG - C4] [GLU - C4] (33)
[[aKG-C4]= VTA -(VTCA+Fl)- +F* (3.3)dt [CIT] [aKG] [GLU]
d [CIT - C2] [aKG - C2] [GLU - C2]
-[aKG- C2] = V [CITC2] (VTCA + F) [KGC2] [GLU-C2] (3.4)
dt [CIT] [aKG] [GLU]
* Glutamate pool
d [aKG - C4] [GLU - C4] (35)[GLU- C4] = F. [ - F,. (3.5)dt [aKG] [GLU]
d [[aKG- C2] [GLU - C2][GLU - C2] = F, F, GLU- ] (3.6)
dt [aKG] [GLU]
* Malate pool
d 1 aKG - C4] [aKG - C2] [MAL - C2]([MAL- C2]C= -Vr ]( + )-(1+ y). V a  (3.7)dt 2 [caKG] [CaKG] [MAL]
The 1/2 introduced in this equation takes into account that there is an
equal mixing of the label at the 2- and 3-carbons of malate. The y term
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represents unlabeled intermediate entering the TCA cycle through
anaplerotic flux while labeled TCA cycle intermediate leaves the cycle
through cataplerotic flux. The anaplerotic flux and cataplerotic flux are equal
in order to maintain constant TCA cycle intermediate pool sizes.
* Oxaloacetate pool
d [MAL - C2](V +F). [OAA - C2] F [ASP- C2] (3.8)
dt [MAL] [OAA] [ASP]
* Aspartate pool
d [OAA-C2] [ASP-C2][ASP - C2] = F2  -F 2  (3.9)dt [OAA] [ASP]
Since the total concentration of citrate, i.e. [CIT], is a constant, we can
rewrite Equation (3.1) as
d [CIT - C4] [CIT - C4][CIT]-- = VrCA F - VrTCAdt [CITI] [CIT]
Define the dimensionless quantity CIT4 as the fraction of citrate that is
13C labeled at the 4-carbon position, i.e.
CIT4 = [CIT - C4]
[CIT]
Therefore, Equation (3.1) can be written as
d V
- CIT4 = r A (F - CIT4)
dt [CIT]
In the same way, we can also define the fractional enrichment variables
for other compartment and rewrite the equations in terms of the
corresponding fractional enrichment levels. Therefore, the pre-steady state
labeling of 13C for each compartment can be described by the following
equations
d V_
- CIT4 =VCA .(F - CIT4) (3.10)
dt [CIT]
d V VTCA +F F
-aKG4 = CIT4 rcA •.KG4 + ' GLU4 (3.11)dt [ aKG] [aKG] [ aKG]
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d F
-GLU4 = F 1 (aKG4 - GLU4) (3.12)
dt [GLU]
d V
- CIT2 = VrTa (OAA2 - CIT2) (3.13)dt [CIT]
d VTCA VTCA +F FF
-daKG2 = CIT2 aKG2 + 1 GLU2 (3.14)
dt [aKG] [ aKG] [ aKG]
d F
-GLU2= 1 .(aKG2 - GLU2) (3.15)
dt [GLU]
d VC 1 1
-MMAL2= -= [-_ aKG2 +-' aKG4 - (1+ y) -MAL2] (3.16)
dt [MAL] 2 2
d V___ V___ +_F_ F_
-OAA2 = rVTC MAL2- VTCA + F2 OAA2 + F2  ASP2 (3.17)dt [OAA] [OAA] [OAA]
d F_
-ASP2 = F2  (OAA2 - ASP2) (3.18)dt [ASP]
Therefore, we have nine linear differential equations (Equations 3.10-3.18)
to describe the pre-steady state labeling of 13C at the 4- and 2-carbon positions
of each metabolite pool in the TCA cycle. These equations characterize the
TCA cycle kinetics by three flux parameters (i.e. VTra, F1, and F2), fraction of
13C acetyl-CoA labeled at 2-carbon (Fe), relative anaplerotic flux (y), and the
corresponding metabolite concentrations. If we use a single 9 x 1 vector q to
represent the fractional enrichment of each compartment as a function of
time, i.e.
CIT4
aKG4
GLU4
CIT2
aKG2
GLU2
MAL2
OAA2
ASP2
[CIT - C4]/[CIT]
[aKG - C4]/[ aKG]
[GLU - C4]/[GLU]I
[CIT - C2]/[CIT]
[ aKG - C2]/[ aKG]
[GLU - C2]/[GLU]
[MAL - C2]/[MAL]
[OAA - C2]/[OAA]
[ASP - C2]/[ASP]
The model can then be described in matrix form as
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Q
d
d q = MTCA q + UAcetyl-CoA (3.19)
where MTCA is a 9 x 9 matrix characteristic of the TCA cycle, its elements are
dependent on the TCA cycle flux (VTCA), the interconversion rates between the
TCA cycle intermediates and glutamate or aspartate (F, and F2), the level of
anaplerosis (y), and the total concentrations of each metabolite. The input
vector, UAcetylCoA , is governed by the fraction of 13C enriched acetyl-CoA
entering the TCA cycle through citrate synthase (Fc). The only non-zero
element in UAcetylCoA is the one corresponding to the labeling of the 4-carbon
position of citrate since all 13C label of acetyl-CoA at 2-carbon enters the TCA
cycle through citrate synthase and results in labeling at the 4-carbon position
of citrate. Therefore, the evolution of q upon switching to the 13C labeled
substrate can be viewed as a linear system in response to a stepwise
stimulation.
3.4 Methods of Kinetic Analysis
Upon switching to the 13C labeled substrate, the initial fractional
enrichment levels of all metabolite pools are 1.1% since the natural
abundance of 13C is 1.1%. The fractional enrichment of glutamate at 4- and 2-
carbon positions over time course can be obtained from in vivo NMR
spectroscopy, corresponding to the detectable signals in the q vector. By
combining the mathematical analysis with NMR observation of the isotope
concentration history of glutamate pool, TCA cycle flux (VTcA) and
interconversion rates between TCA cycle intermediates and amino acid pools
(F, and F2) can be determined by least-square fitting of the kinetic model to
13C enrichment data from NMR spectra. The basic optimization techniques
employed in this project are introduced in this section. Further details can be
found in references (15, 31).
Most algorithms for nonlinear least-square estimation used either of two
approaches. On the one hand, the model may be expanded as a Taylor series
in Gauss-Newton method and corrections to the parameters are calculated at
each iteration on the assumption of local linearity. However, because of the
divergence of successive iterates, this method can have serious convergence
problems with ill-conditioned functions. On the other hand, various
modifications of the steepest descent method have been used, yet these
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methods usually have agonizingly slow convergence after the first few
iterations (27). The Levenberg-Marquardt method uses a search direction
which is a cross between the Gauss-Newton direction and the steepest descent
and is therefore a stable and reliable method (64, 78). In this study, we have
employed the Levenberg-Marquardt method in data fitting.
Let us first rewrite the problem in more standard form. The mathematical
model that describes the labeling kinetics of each individual compartment
can be written as
d
-q(t,p) = MTCA(p) q(t,p)+ UAcetyl-CoA (p) (3.20)dt
where p=[VTCA F1 F2] is the parameter vector to be determined in least-
square optimization. Therefore, q(t,p) clearly indicates that the enrichment
kinetics is a function of both time and flux parameters. The output, s(t,p), of
this linear system, or the NMR detectable glutamate enrichment at 4- and 2-
carbons, is therefore also a function of time and flux parameters. It can be
expressed as
s(t, p) =[GLU4(t)
s(tp)= LGLU2(t)]
=[0 0]00 0(t1
0o 0 0 1 0 0 q(tp)
= C.q(t,p)
Let d(t,p) be the actual NMR measurement of glutamate enrichment over
time. The cost function to be optimized is then of the form
f(p) = erWe
with e=d(t,p)-s(t,p) be the error between experimental measurement and
fitted data. W here is a symmetric weighting matrix. In this particular
problem, we have taken the inverse of the standard deviation of each data
point as the weighting matrix. Define the Hessian matrix H(p)-V 2f(p),
which is the symmetric matrix of second derivatives of f(p), we can now
make a quadratic approximation of f(p) at a certain search point pk
f(p) = f(pk) + V Tf(pk )APk + +(apk )TH(pk )Apk
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where Apk = - pk. The minimum of f(p) in the direction of pk is obtained by
differentiating the quadratic approximation of f(p) with respect to each of the
components of p and equating the resulting expressions to zero to give
Vf(p) = Vf(pk) + H(pk)Apk = 0
Hence, the next search point pk+1 is
pk+1 _ pk = Apk = -[H(pk)]- . Vf(pk)
pk+1 can also be evaluated without performing a matrix inversion, but
instead by solving the following set of linear equations for Apk,
H(pk )Apk = -Vf(pk)
a procedure that often leads to less round-off error than calculating pkl+ via an
inversion of a matrix.
This method is called Gauss-Newton's method. It makes use of the
second-order approximation of f(p) at pk. Thus, it is possible to take into
account the curvature of f(p) at pk and identify better search directions. It is
therefore the fastest method of minimization when it succeeds. But one big
disadvantage of Gauss-Newton's method is that it may proceed to a saddle
point if H(p) is not positive definite. To overcome this problem, Levenberg
(64) and Marquardt (78) have suggested that the Hessian matrix of f(p) be
modified on each stage of search as needed to ensure that the modified
Hessian matrix, fl(p), is positive definite and well-conditioned. The
procedure adds elements to the diagonal elements of H(p)
HI(p) = H(p) + XI
where X is a positive constant large enough to make H(p) positive definite
when H(p) is not. Therefore, the next search point is evaluated by solving
linear equations
[H(pk) + 2tkI]Apk = -Vf(pk)
where the scalar Xk controls both the direction and step length of the search
for the minimum. When Xk is zero, the direction is identical to that of Gauss-
Newton's method. As Xk tends to infinity, the search tends towards a steepest
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descent direction. The Levenberg-Marquardt method therefore uses a search
direction which is a interpolator between the Gauss-Newton direction and
the steepest descent, favoring steepest descent when far from convergence
and the Taylor series solution near the minimum of f(p).
The implementation of the Levenberg-Marquardt method needs the
evaluations of partial derivatives with respect to the parameters to be
optimized. In a nonlinear system with coupled differential equations, this
can only be done iteratively. From Equation (3.20) we have
d q(tp) MTCA(p) dUAcetyl-CoA (P)
= M~cA )*dq(t,p) + .MA q(t,p)+ cety
-•(-q(tP)) = MTCA (P)dp dt dp dp dp
or
d dq(t,p) MTA(P) q(t,p) MTA() Acetyl-CoA (P) (3.21)
dt dp dp dp dp
At the first iteration, for the initial set of parameter estimates po,
Equations (3.20) and (3.21) can be solved in series,
d q(t, p) MTCA (p) 0 q(t, p) UAcetylCoA (P)
S q(t,p) = MTCA(p) MTcA(P) d(,Acetyl-CoA
p JLJdp dp j
Thus giving q(t,p) and dq(t,p) this then allows the new estimates pl to be
dp
computed. This procedure is repeated at each incremental estimation of the
parameter vector until the best fit is achieved.
3.5 Experimental Constraints for Data Fitting
Since maximal ATP generation by glycolysis is only 5-10% of the total ATP
production in aerobic hearts, the rate of myocardial oxygen consumption is
proportional to flux in the citric acid cycle (135). TCA cycle flux can, therefore,
be calculated from the rate of oxygen consumption (MVO 2) with the
knowledge of the substrate that is fueling respiration (51, 98, 137). Taking
acetate and butyrate, which were used in this study, as an example, for the
oxidation of 1 mole of acetate, 3 moles of NADH and 1 mole of FADH 2 are
generated in the TCA cycle, which results in the consumption of 2 moles of
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oxygen in electron transport chain. Hence, the turnover of the TCA cycle is
one half of the oxygen consumption rate. In the case of butyrate oxidation,
since additional NADH and FADH 2 are generated in 0-oxidation, the ratio of
TCA flux to MVO2 is 1:2.5 (Figure 3.3). Therefore, oxygen consumption
provided experimental constraints of the TCA cycle flux for optimization in
kinetic analysis. While the optimal value for TCA cycle flux was obtained
from least-square fitting of the model to dynamic 13C NMR observation, an
additional penalty term that reflects the difference between fitted TCA cycle
flux and the TCA cycle flux calculated from oxygen consumption was added
to the cost function,
2
v -V
f(p) = eTWe+ VTcA VMVO2
where VMvo, is the TCA cycle flux estimated from the oxygen consumption
rate, and aMvo2 is the error associated with the measurement of oxygen
consumption. This allowed the computer to search in a range of estimated
TCA cycle flux from oxygen consumption while taking into consideration the
measurement error and the oxidation of other fuels.
3-Oxidation
Butyrate - Acetyl-CoA .og Acetate
1 NAD +  1 NADH
1 FAD 1 FADH 2
3 NAD +
1 FAD
3 NADH
1 FADH 2
02 H20
Figure 3.3 Metabolic diagram of acetate and butyrate oxidation. Acetate has direct
entry into the TCA cycle via acetyl-CoA. Butyrate, as a four-carbon molecule,
undergoes 0-oxidation to be cleaved into two acetyl-CoA molecules before entering the
TCA cycle. 1-Oxidation generates additional reducing equivalents that require oxygen
to be reoxidized. Therefore, at the same oxygen consumption rate, TCA cycle flux from
butyrate oxidation is slower comparing to acetate oxidation, yet the energy yield is the
same.
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To minimize the number of unknowns in data fitting, acetyl-CoA
enrichment (Fe), and relative anaplerotic flux (y) were determined from
high-resolution NMR spectrum of tissue extracts. Glutamate, aspartate,
citrate, and a-ketoglutarate concentrations were measured by enzymatic
assays. Other metabolite concentrations whose values are less critical to the
enrichment kinetics of glutamate were taken from literature on heart
perfused under similar substrate conditions: malate, 0.60 gmoles/g dry
weight; oxaloacetate, 0.04 (98, 123). TCA cycle flux (VTCA) and interconversion
rates between TCA cycle intermediates and amino acid pools (F, and F2) were
determined by nonlinear least-square fitting of the model to 13C enrichment
data from NMR spectra using the Levenberg-Marquardt method, with the
goodness of the fit evaluated by the correlation coefficient (6).
Two transamination reactions are involved in the exchange of 13C label
between the TCA cycle intermediates and glutamate, one is catalyzed by
alanine aminotransferase (ATA), the other by glutamate-oxaloacetate
transaminase (AAT):
a-Ketoglutarate + alanine "-A , glutamate + pyruvate
a-Ketoglutarate + aspartate GOT glutamate + oxaloacetate
As acetate and butyrate were the major carbon source for oxidative
metabolism in all the experiments, alanine and pyruvate concentrations were
low and alanine aminotransferase activity is minimal. Therefore, the
interconversion rates between a-ketoglutarate and glutamate, and between
oxaloacetate and aspartate were set equal, i.e. F, = F2. The optimization was
performed using MATLAB (The MathWorks Inc., Natick, MA). The
MATLAB programs for data fitting are included in Appendix C.
3.6 Sensitivity Analysis
Measurements of the TCA cycle intermediates that are at very low
concentrations, a-ketoglutarate, malate, and oxaloacetate, are subject to great
statistical fluctuations. To test the robustness of the model to such
measurement errors, the effect of possible variations or errors in these pool
sizes was evaluated by sensitivity analysis. Using parameters obtained from
studies presented in Chapter 4, simulations were performed by perturbing
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each pool size, and changes in 13C turnover in glutamate pool were compared
(Figures 3.4-3.6).
A simultaneous 200% change in pool sizes of a-ketoglutarate, malate, and
oxaloacetate introduces very little change in glutamate labeling kinetics
(Figure 3.4), indicating that even the most dramatic changes in these three
intermediates have very little impact on the dynamics of glutamate 13C
enrichment. Figure 3.5 shows that a 90% change in either citrate or aspartate
level, which is far beyond the experimental error range, also has little effect
on glutamate enrichment curves. Glutamate, however, is by far the most
sensitive pool (Figure 3.6). A 20% increase or decrease in its pool size
introduces significant changes in its labeling curves. When the measurement
is within 5%, this change becomes less important.
0.8
0.6
0.4
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5 10 15 20 25 30
Time (min)
Figure 3.4 Sensitivity analysis. Simulated time course of glutamate enrichment with a
simultaneous threefold increase (dashed lines) or decrease (dotted lines) in pool sizes of
(o-ketoglutarate, malate, and oxaloacetate shows little difference from that of
measured pool sizes (solid lines). The minor impact of TCA intermediates on glutamate
enrichment demonstrates the robustness of estimated parameters when measurements of
TCA cycle intermediates are subject to large statistical fluctuations.
Page -52-
0.8
0.6
0.4
0.2
5 10 15
Time (min)
0.8
0.6
0.4
0.2
20 25 30
10 15 20 25 30
Time (min)
Figure 3.5 Sensitivity analysis. Simulated time course of glutamate enrichment with
90% increase (dashed lines) or decrease (dotted lines) in citrate (upper) or aspartate
(lower) concentrations shows little difference from that of measured pool sizes (solid
lines). This indicates that experimental measurement errors in citrate and aspartate
can be tolerated in kinetic analysis.
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Figure 3.6 Sensitivity analysis. Simulated time course of glutamate enrichment with
20% (upper) or 5% (lower) increase (dashed lines) or decrease (dotted lines) in
glutamate concentration as compared to measured pool size (solid lines). The results
demonstrate that changes in glutamate pool size can significantly affect the glutamate
enrichment kinetics. Therefore, experimental measurement error in glutamate should
be within 5%.
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In summary, pre-steady state enrichment of glutamate is insensitive to
large changes in a-ketoglutarate, malate, and oxaloacetate pool sizes at
physiological levels. Measurement errors in citrate and aspartate can be
tolerated, and the accuracy for glutamate measurement has to be within 5%.
Similar results from sensitivity analysis have also been reported by other
investigators (19, 131).
3.7 Practical Considerations
In this model, 13C label entering the TCA cycle from acetyl-CoA pool is
treated as a step function, with the underlying assumption that acetyl-CoA is
instantly enriched to the level of F, upon the delivery of 13C-enriched
substrate. Since the initial 13C enrichment level of acetyl-CoA is also 1.1%, i.e.
the natural abundant level of 13C, whether or not this assumption is valid
needs to be examined.
The enrichment of acetyl-CoA with 13C upon the delivery of 13C-enriched
substrate can be depicted by the compartment model shown in Figure 3.7,
with fluxes entering and leaving the compartment be the same as the TCA
cycle flux at steady state. However, the flux of 13C label entering the
compartment is only VcA- F, since other endogenous substrate is also
oxidized via the TCA cycle. Therefore, the labeling kinetics for acetyl-CoA
pool can be described by the following equation:
d [131- ACl
--[C- AC] = VTcA- F - VTCAdt [AC]
where [13C- AC] is the concentration of 13C-
enriched acetyl-CoA, and [AC] is the
concentration of the total acetyl-CoA. Let
AC* be the ratio of 13C-enriched acetyl-CoA
to total acetyl-CoA, i.e.
[AC '=3C- AC]AC =[AC][AC]
then Figure 3.7 Compartment model
for acetyl-CoA enrichment.
dAC* VTCA .(F - AC*)
dt [AC]
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To simplify the problem, assume the natural abundance level of 13C is
negligible, or the initial enrichment of acetyl-CoA is zero, i.e. AC*(O)= 0. The
labeling kinetics of acetyl-CoA then follows a simple monoexponential
equation,
AC*(t) = F, [1- exp(- t )1[ AC] / Vc A
Therefore, the time course of acetyl-CoA enrichment occurs as an
exponential function of time, with the time constant being the ratio of acetyl-
CoA concentration in total to the flux through the TCA cycle. Since the
physiological concentration of acetyl-CoA is approximately 0.2 gmoles/g dry
weight only (96), the time constant for the enrichment of acetyl-CoA is very
small. Using the TCA cycle flux determined from experiments in Chapter 4
(10.52 ~ 1.66 jimoles/min/g dry weight), the time constant for acetyl-CoA
enrichment ranged from 0.02 to 0.12 minutes. Therefore, the enrichment
level of acetyl-CoA 10 seconds after delivery of labeled substrate is already 75%
of the steady-state value, by 30 seconds it is 98%. Thus, the assumption of
instant equilibration of acetyl-CoA is a reasonable approximation.
The current model is derived from a simplified compartment model of
the TCA cycle by eliminating several non rate-limiting pools. To justify this
simplification, simulation results of the reduced model was compared with
that of a more comprehensive model that also includes succinate and
fumarate pools along with equations to describe both 2- and 3-carbon labeling
(8 compartments, 19 differential equations) (139). These two models showed
no difference in characterizing 13C labeling kinetics of glutamate. A closer
examination of the fractional enrichment of succinate, malate, and fumarate
as a function of time shows that the downstream compartment follows the
labeling pattern of the previous compartment very closely. This similarity in
labeling dynamics of the TCA cycle intermediates is perhaps due to a
relatively large TCA cycle flux as compared to the concentrations of the TCA
cycle intermediates which are usually on the order of less than 1 gmole/g dry
tissue weight.
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Chapter 4
Changes in 13 C Turnover in Glutamate
due to TCA Cycle Flux
This study was aimed at developing dynamic methods of 13C NMR
detection and techniques of kinetic data analysis to quantify rate-limiting
events within intact hearts. Specific aims of this study were:
1) to establish the kinetic modeling method in the analysis of dynamic 13C
NMR spectra;
2) to test the capacity of the model by introducing various perturbations to
the metabolic system;
3) to identify rate-limiting steps in isotope enrichment of glutamate by
kinetic analysis method.
Experiments were designed to monitor 13C enrichment rates within the
glutamate pool of isolated hearts. Dynamic 13C NMR spectroscopy was used
to assess the influences of physiological demand and metabolic flux on the
turnover of 13C label in the intact heart. Studies were aimed at testing the
relative contributions of the TCA cycle flux and the interconversion rate
between a-ketoglutarate and glutamate to the presteady-state evolution of 13C
label within the NMR detectable glutamate pool. Isotope kinetics was
evaluated with the manipulation of the TCA cycle flux secondary to either
activity through P-oxidation (acetate versus butyrate) or altered metabolic
demand (mechanical work versus basal metabolic state). Comparison of
glutamate-oxaloacetate transaminase rate to isotope exchange rate allowed
potential rate-limiting steps in glutamate enrichment to be identified.
4.1 Using Substrate and Workload to Change the Metabolic State of the
System
Two short chain fatty acids, acetate (CH3-COO-) and butyrate (CH3-CH 2-
CH 2-COO'), were chosen as the substrate in this study since fatty acids are the
preferred substrate for myocardium. Although both acetate and butyrate are
short chain fatty acids, their entry into the TCA cycle takes a different
pathways and are, therefore, regulated differently. Acetate, having only two
carbon atoms, is transported directly into the mitochondria and is thereby
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converted to acetyl-CoA by mitochondrial acetate synthetase. It is readily
oxidized by the perfused heart and causes an elevation of acetyl-CoA levels
(86).
ATP AMP + PPi
0
CH3 -COO + CoASH CH, -C-S-CoA
synthetase
On the other hand, butyrate, as a four-carbon fatty acid, undergoes one
turn of P-oxidation to be cleaved into two acetyl-CoA molecules before it is
oxidized by the TCA cycle (Figure 1.3). Since 1-oxidation is inhibited by high
mitochondrial redox state, the increase in acetyl-CoA is less significant then
acetate oxidation. Furthermore, 1-oxidation of butyrate also generates
additional reducing equivalents that are energy yielding and require oxygen
to be reoxidized. Thus, at the same workload, 1-oxidation also generates
energy required by the myocardium, and less energy is derived from the TCA
cycle. As a consequence, the TCA cycle flux from butyrate oxidation is slow
compared to acetate oxidation when oxygen consumption rate is the same. In
this way, butyrate induces changes in the TCA cycle activity without changing
the respiratory rate and contractile performance of the myocardium.
Therefore, while 13C-enriched acetate has direct entry and rapid turnover of
label in the TCA cycle, 13C-enriched butyrate offers regulated entry of label
into the TCA cycle through P-oxidation.
It is necessary to point out that neither acetate nor butyrate are
physiological substrates for the in vivo hearts. However, these two substrate
present the simplest scenario for studies that aim at the characterization of
rate-limiting steps in isotope kinetics, while more physiological substrates,
such as long chain fatty acids, would introduce new rate-limiting steps in the
incorporation of label into the glutamate pool, i.e. activation and transport of
long chain fatty acids into the mitochondria (11). Therefore, the choice of
acetate and butyrate as the sole exogenous substrate offers a simple, well-
controlled model that serves the purposes of this study well.
The energy requirement of the heart is thought to consist of a basal
component utilized in maintaining the viability of myocardial tissue, while
contraction is associated with further oxygen consumption and ATP
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generation in proportion to work performed (85). Previous investigations
have determined that the basal metabolism of the heart comprises 10 to 20%
of the total myocardial oxygen consumption and ranges from 5 to 10
gmoles/min g dry weight (8, 134). The heart is capable of responding to a
wide range of load demands by an increase of metabolic activity, without
significant changes in the myocardial contents of adenine nucleotides,
creatine phosphate, and the TCA cycle intermediates. Previous studies with
the isolated perfused heart have established an approximately linear
correlation between cardiac work and oxygen consumption (8, 66, 85). Hence,
changes in workload can introduce another perturbation to the metabolic
system by changing the metabolic activity of the heart.
In this study, metabolic activity of heart at normal workload was
compared to heart at basal metabolic state. Basal metabolism was achieved by
supplying the heart with an excess amount of potassium (potassium arrest).
High extracellular concentration of potassium decreases the cellular resting
membrane potentials so that myocyte contractions are no longer generated.
Once contraction is abolished, energy is used mainly for maintenance of the
cell ionic milieu (e.g. the Na+-K+ ATPase) and macromolecular synthesis (7).
There were four experimental groups in this study. They were comprised
of hearts perfused with 1) 2.5 mM acetate (n=7); 2) 2.5 mM butyrate (n=7); 3)
2.5 mM acetate + 20 mM KC1 (n=5); and 4) 2.5 mM butyrate + 20 mM KC1
(n=5). Additional experiments were done with hearts perfused with [2, 4-13C]
butyrate at normal workload to eliminate the partial labeling of acetyl-CoA
from f-oxidation (n=4). At the start of each protocol, heart was perfused with
either unlabeled acetate or butyrate for 10 minutes to reach metabolic
equilibrium according to the experimental protocol described in Chapter 2.
The substrate supply was then switched to the corresponding 13C-labeled
substrate: either [2-13C] sodium acetate or [2-13C] sodium butyrate (Isotec Inc.,
Miamisburg, OH), with or without KC1. Sequential 13C spectra were then
acquired every 1.25 (acetate, 32 free induction decays) or 2.5 (butyrate, 64 free
induction decays) minutes until steady-state enrichment was reached.
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4.2 Experimental Results
4.2.1 Contractile Function and Oxygen Consumption
Mechanical performance and oxygen consumption are tabulated in Table
4.1. Contractile function, assessed by rate-pressure-product (RPP), was similar
for hearts at normal workload, and was maintained throughout the
experiment as shown in Figure 4.1. Since acetate and butyrate have similar
P:O ratio (2.75 for acetate and 2.8 for butyrate), oxygen consumption rate was
also similar. The oxygen consumption ([tmoles/min/g dry weight) to rate-
pressure-product ratio (103 mmHg/min) was 1.27 in acetate group and 1.18 in
butyrate group, similar to that reported by other investigators in isolated rat
heart (8).
Table 4.1 Contractile function and oxygen consumption data.
HR LVDP RPP MVO2
(beats/min) (mmHg) (mmHg/min) (pmoles/min/g dw)
Acetate 161±49 101±14 16,000-4,300 20.30±5.49
Butyrate 159±43 109±+25 17,300-_6,000 20.45±4.59
Acetate+KC1 - - 7.45±1.39*
Butyrate+KCI - - 6.88±2.98*
HR, heart rate. LVDP, left ventricular developed pressure. RPP, rate-pressure-product.
MVO2, oxygen consumption. RPP is used as an index of contractile performance. All data
are presented as MeanI+SD. (* p<0.05 as compared to heart at normal workload.)
Hearts arrested with KC1 generated no mechanical work. As expected,
their oxygen consumption was significantly lower, only 34-37% of that of
hearts at normal workload. These results are consistent with both previous
findings (66) and data from canine and rat hearts reported by other
investigators (8, 62). Thus, the protocol afforded analysis of 13C kinetics at
normal and basal metabolic rates in both the absence and presence of
significant effects on the TCA cycle flux from additional NADH and FADH 2
generation by P3-oxidation.
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Figure 4.1 Functional stability over time. Contractile performance was maintained
throughout the experiment in both groups. Open circle: acetate perfused heart; closed
circle: butyrate perfused heart.
4.2.2 Energetic State of Phosphate Metabolism
Representative 31P spectra from heart at both normal workload and
potassium arrest are shown in Figure 4.2. Consistent with previous findings
(66), hearts at basal metabolic state showed no difference in high energy
phosphate metabolism over the course of perfusion. PCr to ATP ratios
ranged from 1.84 to 2.49 and were similar among the four experimental
groups. These data are also similar to those reported previously with
pyruvate or lactate perfused hearts under the same NMR acquisition
parameters (68, 72). Therefore, phosphorylation potentials were similar in all
four experimental groups.
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Figure 4.2 Representative 31P spectra from heart perfused with acetate. Labeled peaks
are inorganic phosphate (Pi), phosphocreatine (PCr), and the three phosphates of ATP
(ATPa, ATPp, and ATPy). (A) at normal workload; (B) at potassium arrest.
4.2.3 Metabolite Contents
Steady-state metabolite contents are tabulated in Table 4.2. Values are in
agreement with those measured by other investigators with similar
experimental conditions (98, 123). At normal workload, heart perfused with
acetate has a higher level of citrate than heart perfused with butyrate
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(p=0.012). This increase in citrate level can be explained by the so-called
"unspanning" (98, 99) of the TCA cycle at high acetyl-CoA level with acetate
perfusion, which causes the rate of citrate and isocitrate synthesis to exceed
the flux through the rest of the TCA cycle (10, 97). The accumulation of citrate
induces a shift in the glutamate-oxaloacetate transamination (10). Therefore,
the aspartate level in acetate perfused heart appears to be lower than butyrate
perfused heart (p=0.001), and correspondingly, the glutamate level with
acetate perfusion is slightly higher (p=0.047). This shift in metabolite contents
was not observed in heart at potassium arrest, probably due to the strong
inhibition of the cycle when ATP and NADH levels were high with low
energy demand.
Table 4.2 Steady state metabolite contents.
Glutamate a-Ketoglutarate Citrate Aspartate
Acetate 27.73±3.82 0.50±0.35 1.35±0.68 1.56±0.80
Butyrate 25.12±4.78* 0.59±0.31 0.84±0.34* 2.60±1.01*
Acetate+KC1 22.64±6.16 0.74+0.09 1.10±0.30 1.14±0.24
Butyrate+KCI 21.05±7.36 0.91±0.41 1.05±0.52 0.95±0.40
Metabolite contents are determined by enzymatic assays. All data are presented in Mean±+SD
and are given as pmoles/g dry tissue weight. (* p<0.05 as compared to acetate perfusion)
4.2.4 13C NMR of Tissue Extracts
Proton decoupled 13C spectra of tissue extracts from hearts at both normal
workload and basal metabolic state are shown in Figure 4.3 and Figure 4.4.
Quantitatively, the multiplet components of spectra from potassium arrested
hearts were similar to that of hearts oxidizing the same substrate at normal
workload. [2-13C] Butyrate induced a lower level of doublet signal from
glutamate 4-carbon resonance because only 50% [2-12C] acetyl-CoA, at most,
entered the TCA cycle after butyrate was cleaved to produce two acetyl-CoA
molecules by j-oxidation.
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Figure 4.3 Glutamate resonances from high resolution 13C NMR spectra of tissue
extracts of [2-13C] acetate perfused hearts. (A) At normal workload; (B) With
potassium arrest.
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Figure 4.4 Glutamate resonances from high resolution 13C NMR spectra of tissue
extracts of [2-13C] butyrate perfused hearts. (A) At normal workload; (B) With
potassium arrest.
The fraction of 13C enriched acetyl-CoA entering the TCA cycle (F,) and
the ratio of anaplerotic flux to citrate synthase activity (y) calculated from
high resolution 13C NMR spectra are presented in Table 4.3. The calculated
F, and y values showed no statistically significant difference with the same
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perfusate supply. As expected, F, values with hearts oxidizing [2-1 3C] butyrate
at both normal workload and with potassium arrest were less than 50%, only
half of those with hearts oxidizing [2-13C] acetate due to the enrichment
difference discussed above.
Table 4.3 Fc and y values from high resolution NMR spectra.
Fc y
Acetate 91.6±5.9 8.2±4.1
Butyrate 46.2±4.1 14.7±8.7
Acetate+KC1 91.9±1.5 11.4±5.3
Butyrate+KCl 46.8±4.2 22.1±11.8
Fc, fraction of 13C-enriched acetyl-CoA entering the TCA cycle. y, ratio of anaplerosis
to citrate synthase activity. Values of Fc and y were determined from high-resolution
NMR spectra of tissue extracts. Data are presented in Mean+SD.
4.3 Kinetic Analysis of Dynamic 13C NMR Data
Figure 4.5 and 4.6 show representative, sequential 13C NMR spectra of
intact hearts from each experimental group. The label first appeared in the 4-
carbon position of glutamate and subsequently in the 2- and 3-carbon
positions as described in Chapter 3. Since acetate is readily converted to
acetyl-CoA while butyrate undergoes regulated f-oxidation, resonance signal
from butyrate is much higher than that from acetate. Not surprisingly, label
appeared much slower in hearts at basal metabolic state (Figure 4.6) as
compared to hearts at normal workload (Figure 4.5) due to reduced metabolic
rate. However, the incorporation of label into the glutamate pool with [2-13C]
butyrate was also significantly delayed in reaching steady-state as compared to
hearts oxidizing [2-13C] acetate. This delay is evident in Figure 4.7 and 4.8
which show the time course of 13C enrichment of glutamate at 2- and 4-
carbons from all acquired spectra along with the results from least-square
fitting.
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Figure 4.5 Dynamic 13C spectra of isolated rabbit hearts at normal workload. Spectra
were acquired during a period of 1.25 (A) or 2.5 (B) minute. Labeled substrates were 2.5
mM [2-13C] acetate (A) and 2.5 mM [2-13C] butyrate (B). Heart oxidizing acetate
reached steady state in 30 minutes, while heart oxidizing butyrate reached steady
state in 40 minutes. Identified resonance peaks are: GLU-C2, 2-carbon of glutamate;
GLU-C4, 4-carbon of glutamate; GLU-C3, 3-carbon of glutamate; ACE-C2, 2-carbon of
acetate; BU-C2, 2-carbon of butyrate.
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Figure 4.6 Dynamic 13C spectra of isolated rabbit heart at potassium arrest. All
spectra are acquired within 2.5 minutes. Labeled substrates were 2.5 mM [2-13C] acetate
(A) and 2.5 mM [2-' 3C] butyrate (B).
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The delayed approach to steady state with hearts oxidizing butyrate was
quantified by the time constants of the labeling curves from a single
exponential fit: in the acetate group, 7 min for the 4-carbon of glutamate (C4),
17 min for the 2-carbon (C2); in the butyrate group, 10 min for C4, and 32 min
for C2. In potassium arrested hearts, the time constants were: with acetate, 14
min for C4, 46 min for C2; with butyrate, 21 min for C4, and 97 min for C2.
However, these time constants can not be used as a direct index of the TCA
cycle flux since the exchange of label between a-ketoglutarate and glutamate
can also affect the labeling kinetics of glutamate.
Results from nonlinear least-square fitting of the kinetic model to
glutamate labeling are shown in Figure 4.7 and 4.8. In all four groups, a good
agreement of the model to the experimental data was evident. TCA cycle flux
(VrCA) and interconversion rate between a-ketoglutarate and glutamate (F1)
determined from data fitting are presented in Table 4.4 with the standard
deviation calculated from the Jacobian matrix of the model. Potassium
arrested hearts showed significantly reduced TCA cycle flux, only 21-27% of
that of hearts at normal workload. On the other hand, hearts oxidizing
butyrate also have reduced TCA cycle activity as compared with hearts
oxidizing acetate, despite similar oxygen consumption and workload. The
result is due to the P-oxidation of butyrate as additional reducing equivalents
are generated to meet the energy requirement of the myocardium at a
correspondingly lower TCA cycle flux. The interconversion rate between a-
ketoglutarate and glutamate was also slower in hearts perfused with butyrate.
In combination, the reduced TCA cycle flux and the slower interconversion
rate accounted for a general delay in the observed 13C enrichment curve from
hearts oxidizing butyrate.
Table 4.4 Flux parameters determined from kinetic analysis.
TCA flux Interconversion rate r2
Acetate 10.52±0.35 10.67±1.01 0.98
Butyrate 8.00±0.23 4.35±0.30 0.99
Acetate+KC1 2.87±0.13 6.52+1.11 0.99
Butyrate+KCI 1.66±0.11 4.08±0.92 0.99
Data are presented in Mean+SD and are given as gmoles/min/g dry tissue weight.
Correlation coefficient r2 indicates the goodness of fitting.
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Figure 4.7 Time course of glutamate 13C enrichment from NMR measurement and kinetic
analysis. Hearts were supplied with either 2.5 mM [2-13C] acetate (upper) or 2.5 mM
[2-13C] butyrate (lower). Signal intensities from dynamic 13C NMR spectra are
normalized to steady-state enrichment levels of the 4-carbon of glutamate. NMR data
are shown in open and closed circles. Open circles, 13C enrichment level of glutamate at
4-carbon position; closed circles, 13C enrichment level of glutamate at 2-carbon position.
Solid lines are fitted enrichment curves from kinetic analysis.
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Figure 4.8 Time course of glutamate 13C enrichment from NMR measurement and kinetic
analysis. Hearts were at potassium arrest and were supplied with either 2.5 mM [2-
13C] acetate (upper) or 2.5 mM [2-13C] butyrate (lower). Figure legends are the same as
Figure 4.7.
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4.4 Effects of Fractional Enrichment on 13C Turnover in Glutamate
When the heart was supplied with [2-1 3C] butyrate, only 50% of the acetyl-
CoA generated from the P-oxidation of butyrate was 13C enriched at 2-carbon.
To test whether this partial enrichment of acetyl-CoA imposed an impact on
the enrichment kinetics of glutamate, another set of experiments (n=4) was
performed to supply the hearts with [2, 4-13C] butyrate so that both acetyl-CoA
molecules generated from P-oxidation were labeled at 2-carbon. 13C spectra
from tissue extracts showed elevated doublet signal in the glutamate 4-carbon
resonance (Figure 4.9), resembling that of a heart perfused with [2-13C] acetate
(Figure 4.3). As expected, acetyl-CoA enrichment increased to 92.0±1.4%,
comparable to that of hearts oxidizing acetate (91.6±5.9%). Yet anaplerosis was
similar to hearts perfused with [2-13C] butyrate: y=13.4±0.2%. Despite this
high acetyl-CoA enrichment level, the dynamics of glutamate enrichment
showed little difference from hearts oxidizing [2-13C] butyrate (Figure 4.10).
Using the same flux parameters obtained from curve fitting to data from the
[2- 13C] butyrate group, the simulated enrichment curves were in good
agreement with the experimental data (Figure 4.10). Therefore, the observed
delay in glutamate labeling from hearts perfused with butyrate was induced
by differences in metabolic activity rather than the dilution of label.
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Figure 4.9 Glutamate resonances from high resolution 13C NMR spectra of tissue extract
of [2, 4-13C] butyrate perfused heart. The multiplet structures resemble that of [2-13C]
acetate perfused heart.
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Figure 4.10 Glutamate 13C enrichment from heart oxidizing [2, 4-13C] butyrate. Open
and closed circles are NMR measured 13C enrichment levels of 2- and 4-carbons of
glutamate from hearts perfused with [2, 4-13C] butyrate (n=4). Solid lines are the
simulated enrichment curves by using the same flux parameters obtained from kinetic
analysis of [2-13C] butyrate data presented in Table 4.4. The good agreement between
simulated curves and experimental data is demonstrated.
4.5 Simulation of Glutamate Enrichment Using Transaminase Flux as the
Exchange Flux between TCA Cycle Intermediates and Glutamate
The actual chemical exchange of 13C label between ca-ketoglutarate and
glutamate from the TCA cycle occurs through a transamination reaction that
also involves oxaloacetate and aspartate, and the enzyme catalyzes the
reaction is therefore called glutamate-oxaloacetate transaminase (GOT), or
aspartate aminotransferase (AAT). Two isoforms of GOT exist, mitochondrial
and cytosolic. Although the catalytic mechanism of GOT has been extensively
explored and fully elucidated (79, 84, 119), the reaction rate of GOT for rabbit
heart has not been characterized.
In collaboration with Dr. LaNoue at the Hershey Medical Center of
Pennsylvania State University, kinetic parameters of both cytosolic and
mitochondrial GOT were measured in an effort to characterize the
transaminase rate in in vivo heart. The measured Km and Vmax values of
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GOT were presented in a published manuscript (140). Briefly, for the cytosolic
GOT, Vmax is 1.62 tmoles/min/mg total heart protein, and Km for aspartate
and a-ketoglutarate are 2.72 mM and 0.12 mM respectively. Based on these
measured values and metabolite contents (Table 4.2) flux through GOT (FGOT)
can be calculated according to ping-pong reaction kinetics (127), i.e.
F Vmax
FGOTGOT = KASP KaKG1+ m + m[ASP] [aKG]
Presented in Table 4.5 are the calculated in vivo GOT fluxes in all four
experimental groups. In the calculation, heart protein to tissue weight ratio
was taken as 683 mg total heart protein/g dry tissue weight and the volume to
tissue weight ratio was 2 ml/g dry tissue weight (44). Since the transaminase
reaction occurs mainly in the cytosol, kinetic parameters from cytosolic GOT
were used in the calculation. a-Ketoglutarate and aspartate contents
expressed in mM are also shown in Table 4.5 for comparison to their
corresponding Km values. It shows that a-ketoglutarate contents in all four
groups are above its Km of GOT, while aspartate contents are below.
Therefore, aspartate concentration is the dominant factor in transamination
rate. Hence, FoOT was highest in the butyrate group due to a high aspartate
concentration.
Table 4.5 Flux through glutamate-oxaloacetate transaminase.
[ASP] (mM) [aKG] (mM) FGOT  FGOT/VTCA FGOT/F 1
Acetate 0.78 0.25 223 21 21
Butyrate 1.30 0.30 316 40 73
Acetate+KC1 0.57 0.37 181 63 28
Butyrate+KC1 0.48 0.46 159 96 39
FGOT: flux through glutamate-oxaloacetate transaminase (GOT) in gtmoles/min/g dry tissue
weight; VTCA: flux through the TCA cycle; FI: interconversion rate between a-ketoglutarate and
glutamate. Both VTCA and F2 were determined from kinetic analysis.
Also shown in Table 4.5 are the ratios of FGOT / VTCA and FoOT/IF. The data
demonstrate that the flux through GOT is indeed much faster than the flux
through the TCA cycle. However, contrary to previous assumptions, the
interconversion rate between a-ketoglutarate and glutamate (F,) determined
from least-square fitting of the model is at least 20 times slower than flux
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through GOT (FGOT) in all four groups and is on the order of the TCA cycle
flux. These data suggest that another rate-limiting step exists in the labeling
of glutamate.
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Figure 4.11 Difference between transaminase rate and interconversion rate. Using flux
through glutamate-oxaloacetate transaminase (GOT) calculated from measured Vmax
and Km of GOT as the exchange rate between a-ketoglutarate and glutamate, the
simulated time course of glutamate 13C enrichment (dotted lines) shows very poor
agreement with the experimental data (circles, acetate group). Open circles: measured
13C enrichment level of glutamate at 4-carbon; closed circles: measured 13C enrichment
level of glutamate at 2-carbon. Solid lines: simulated time course of glutamate 13C
enrichment using flux parameters determined from least-square fitting (acetate group).
Data fitting was also performed in the absence of the constraint provided
by measured oxygen consumption. Removing this constraint caused a 9%
deviation in TCA cycle flux and a 14% deviation in interconversion rate from
the values obtained using the constraint. However, the interconversion rate
remained on the order of the TCA cycle flux and was also significantly slower
than the calculated GOT flux. A fixed TCA cycle flux, calculated from the
lower limit of oxygen consumption, was also used so that only the
interconversion rate was determined from data fitting, yielding increased
interconversion rate for each group. However, these interconversion rates
remained an order of magnitude lower than the GOT flux. If FGOT alone was
used to represent the isotope exchange rate, then simulated enrichment
curves showed poor agreement with experimental data. The results of this
test are shown in Figure 4.11. Therefore, flux through GOT is not the rate-
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limiting step in the exchange between ct-ketoglutarate and glutamate. This
slow exchange rate might be a result of metabolite transport due to metabolite
compartmentation, as the TCA cycle enzymes are intramitochondrial while a
significant fraction of glutamate is cytosolic.
4.6 Discussion
In this study, changes in oxidative metabolism were studied at different
workload demands and metabolic rates using 13C NMR spectroscopy. The
influence of these differences on the turnover of the 13C label within the
NMR-detectable glutamate pool were systematically examined. Dynamic 13C
spectra, reflecting the evolution of enrichment in the glutamate pool, were
acquired with 1.25 or 2.5 minute temporal resolution from intact, functioning
hearts. Oxygen consumption and mechanical performance in response to
distinctly different physiological demands and metabolic regulation were
constantly monitored during the acquisition of NMR spectra. Data acquired
in this mode were analyzed with a kinetic model to determine metabolic
fluxes and rate-limiting steps. The model was tested for its sensitivity to
metabolite contents, respiratory rate, and transaminase activity from four
experimental groups. Measured physiological constraints provided the
experimental range of data fitting. The model integrates data from enzymatic
assays, high resolution 13C NMR data from tissue extracts, and dynamic
changes in 13C NMR spectra from intact hearts to evaluate metabolic
regulation in functioning organs. From this study, both TCA cycle flux and
the interconversion rate between metabolite pools were determined from the
evolution of 13C NMR signals from intact hearts for comparison to
experimentally measured enzyme kinetics.
The current simplified model is a modification of that developed by
Chance et al. (17). By considering the total labeling of carbons at 2-, 3-, and 4-
carbons instead of individual isotopomer, it was possible to take the
advantage of the symmetry in isotope labeling at the 2- and 3-carbon positions
of the metabolic intermediates to reduce the number of equations necessary to
represent the entire model. Consequently, only nine differential equations
were needed in representing the kinetics of isotope turnover within the
glutamate pool. Sensitivity analysis was also performed to test the robustness
of the model to changes in TCA cycle intermediates. By incorporating data
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from the analysis of high resolution 13C spectra of heart extracts, anaplerosis
and substrate utilization were also accounted for in kinetic analysis, leaving
only two parameters to be fitted from the model. Therefore, this model has
the advantage of being simple in its formality and yet including as much
biological information as possible with a minimal number of adjustable
unknowns.
Oxidative metabolism in response to various workload has been
previously investigated using 13C NMR spectroscopy and delayed
incorporation of 13C label into the glutamate pool for hearts at lower
workload or basal metabolic state was reported (66, 131). In this study, in
addition to changed workload condition, substrates with different metabolic
pathway (P-oxidation versus no f-oxidation) were used to investigate the
effect of metabolic control on the kinetics of glutamate enrichment. Hearts
oxidizing butyrate showed similar contractile performance as hearts oxidizing
acetate. The oxygen consumption rate was also similar. When partial
labeling of acetyl-CoA from [2-13C] butyrate oxidation was accounted for, the
utilization of exogenous substrate for both substrates was also similar.
Despite all these similarities, the time course of 13C enrichment in glutamate
pool for hearts oxidizing butyrate showed a significantly delayed approach to
steady-state in both normal and KC1 arrested hearts. When [2, 4-13C] butyrate
was used as the substrate, the fraction of 13C enriched acetyl-CoA reached the
same level as hearts oxidizing [2-13C] acetate, yet kinetics of glutamate
enrichment remained unchanged. Kinetic analysis show that this delay is
largely due to a slower TCA cycle flux, which is consistent with the metabolic
regulation of butyrate oxidation as additional reducing equivalents are
generated in 3-oxidation to reduce the demand of energy production from the
TCA cycle.
Substrate utilization and relative flux of anaplerosis were also determined
from high resolution NMR spectra of tissue extracts. While substrate
utilization was found to be the same for both short chain fatty acids regardless
of working conditions, the ratio of anaplerosis to citrate synthase activity (y)
increased slightly at basal metabolic state (Table 4.3). However, care must be
taken in interpreting y values, which is an index of relative contribution of
anaplerosis to TCA cycle activity. Although y increased slightly with
potassium arrested hearts, the calculated anaplerotic flux (y x VTcA) was, on the
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other hand, lower than that of hearts at normal working conditions: 0.86
.imoles/min/g dry tissue weight with acetate only; 0.33 with acetate plus KC1;
1.18 with butyrate only; 0.37 with butyrate plus KC1. Therefore, while hearts
at the same workload condition have similar anaplerotic flux, hearts at basal
metabolic state have a relatively lower anaplerotic flux due to lower energy
requirement.
An important consideration of earlier applications of 13C dynamics is the
omission of potential rate-limiting steps beyond that of TCA cycle flux alone
(17, 34, 81, 82). While a potential effect of the transaminase rate on glutamate
labeling was experimentally demonstrated by Weiss et al using a
transaminase inhibitor (133), the physical compartmentation of the glutamate
and TCA cycle intermediates must also be considered. This is important,
because the GOT enzyme is not allosterically regulated and that the reaction
rate is governed by the specific activity of the enzyme in the myocardium and
the concentrations of the reactants in the tissue. Indeed, the characterization
of the glutamate-oxaloacetate transaminase kinetics shows that the reaction
rate of the transaminase is at least 20 times faster than the TCA cycle turnover
(Table 4.5). However, kinetic analysis of glutamate labeling of intact hearts
has suggested a significantly slower exchange rate between a-ketoglutarate
and glutamate. It is on the order of TCA cycle flux in all four experimental
groups. Since most of the tissue glutamate is located in the cytosol while the
TCA cycle enzymes are located in mitochondria, there is membrane transport
involved in addition to chemical exchange. Therefore, the findings of this
study suggest that the slower exchange rate found in intact hearts is due to the
transport of a-ketoglutarate across the mitochondrial membrane.
If the exchange of label between a-ketoglutarate and glutamate is rate-
limiting, then the rate of isotope enrichment of glutamate will not precisely
reflect isotope incorporation rates into the TCA cycle intermediates. Figure
4.12A shows the simulated time course of 13C enrichment for both glutamate
and a-ketoglutarate by using flux parameters determined from the acetate
group. It is obvious that pre-steady state enrichment of glutamate has a
significant delay as compared to the enrichment of a-ketoglutarate. Although
only the group of hearts oxidizing acetate at normal workload is shown here,
the other three groups showed similar delay in glutamate enrichment.
Furthermore, since 0a-ketoglutarate is in constant chemical exchange with
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glutamate, its labeling kinetics is ultimately determined by both TCA cycle
flux and the exchange rate between a-ketoglutarate and glutamate. Therefore,
even the enrichment of a-ketoglutarate cannot be simply regarded as an
index of the TCA cycle. As can be seen from Figure 4.12B, the time course of
a-ketoglutarate enrichment is very different from that of citrate, in which
enrichment is solely determined by the TCA cycle flux.
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Figure 4.12 Simulated time course of 13C enrichment of citrate, a-ketoglutarate and
glutamate. Flux parameters are determined from least-square fitting of the kinetic
model to NMR data in hearts oxidizing [2-13C] acetate at normal workload.
Differences in the enrichment kinetics between a-ketoglutarate (dotted lines) and
glutamate (solid lines) (A), and between citrate (solid lines) and (-ketoglutarate
(dotted lines) (B) are demonstrated here.
Metabolite contents in the whole cell have been used as the pool sizes in
the kinetic model, making the tacit assumption that the gradients of these
metabolites across the mitochondrial membrane are not large. Distribution of
metabolites between the mitochondria and cytosol has been measured in
perfused livers (118) using techniques difficult to apply to myocytes. These
direct measurements have in fact never been made on heart tissue.
However, conclusions can be drawn about the size of these metabolite
gradients from studies of isolated mitochondria where the mitochondria
have been rapidly separated from media for analysis (60), or where the NMR
signal of metabolites inside the mitochondria can be distinguished from
NMR signals of the external metabolites (43, 80). From these studies, the
mitochondrial gradient of TCA cycle intermediates and glutamate and
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aspartate can be considered to be lower in heart than in liver. In liver, a
proton-linked glutamate transporter permits the formation of a glutamate
gradient that is proportional to pH gradient across the mitochondrial
membrane. The activity of this transporter is very low in heart, to the extent
that glutamate influx into the mitochondria is determined by exchange of
glutamate for aspartate. In liver, a transporter exchanges dicarboxylic acids for
phosphate across a phosphate gradient that is supported by pH gradient (43,
80). However, the activity of the phosphate/dicarboxylate transporter in heart
is very low and TCA cycle intermediates cross the mitochondrial membrane
only via exchange with each other. Therefore, the assumption that the total
intermediate pool sizes can be used as estimates of cytosolic fractions is valid.
Cytosolic glutamate fraction can be calculated from data obtained with
isolated mitochondria. Transport of glutamate into heart mitochondria
occurs almost exclusively via the glutamate/aspartate exchange transporter
(59, 125). Thus, the total of glutamate plus aspartate content in mitochondria
is constant at approximately 12 nmoles/mg mitochondrial protein (55), or 3.0
gmoles/g dry heart weight since the total mitochondrial protein to tissue
weight is 250 mg/g dry weight (44, 135). This is the maximal concentration for
mitochondrial glutamate, whereas total glutamate content ranged from 21 to
28 gmoles/g dry heart weight. Thus, a very large fraction of the glutamate
pool (86-89%) is located in the cytosol. Therefore, 13C NMR detection of
isotope exchange between uc-ketoglutarate and glutamate relies on the efflux
of a-ketoglutarate from the mitochondria to the cytosol, which is
accompanied by malate influx through an electroneutral malate/a-
ketoglutarate antiport carrier in the malate-aspartate shuttle system (58, 59,
105).
Since glutamate and aspartate can both be distributed between the cytosol
and the mitochondria, the interconversion rate between a-ketoglutarate and
glutamate is really a lumped factor that involves both transaminase flux and
transport rate. In the calculation of transaminase flux, due to the small
mitochondrial space compared to cytosolic space and consistency of the
mitochondrial glutamate plus aspartate pool, the majority of the metabolites
are located in the cytosol. Data from isolated mitochondria suggest that
mitochondrial content of glutamate and aspartate is approximately 12
nmoles/mg mitochondrial protein (55), aspartate alone is 1 nmole/mg
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mitochondrial protein (56), and a-ketoglutarate is 0.4 nmoles/mg
mitochondrial protein (60). This implies that 84% of the aspartate and 80% of
the a-ketoglutarate are located in the cytosol. If correction is made according
to these values, the calculated transaminase flux in the acetate group would
be 192 gmoles/min/g dry tissue weight. However, this correction introduced
no change to the simulated enrichment curves in Figure 4.11 (dotted lines),
and therefore, still can not account for the significantly slower
interconversion rate determined from kinetic analysis.
The interaction of the malate-aspartate shuttle with the TCA cycle
provides a likely mechanism for the communication and coordination
between mitochondrial and cytosolic metabolism (61). The relatively slow
interconversion rate that was observed in the current set of experiments
could be due to the influence of the malate-aspartate shuttle which transports
several intermediates involved in the exchange of label. The process may be
further influenced by shifts in the balance of these intermediates in response
to changes in intracellular redox state (68). This study represents the first
experimental evidence that this process is another rate-limiting step in
determining the enrichment rate of glutamate. Thus, dynamic observations
of intact tissues with 13C NMR spectroscopy offer the opportunity to explore
metabolic regulation at the level of both TCA cycle flux and the
communication between intra- and extramitochondrial compartments.
In summary, sequential 13C NMR spectra were obtained from intact hearts
at either normal workload or basal metabolic state during perfusion with 13C-
enriched acetate or butyrate. A kinetic model was developed for the analysis
of 13C enrichment data to evaluate the regulations in oxidative metabolism
and to identify rate-limiting steps in glutamate enrichment. From this
analysis, the interconversion rate between glutamate and a-ketoglutarate was
found to be slow relative to the transaminase rate from measured enzyme
kinetics. Thus, the exchange of the glutamate pool with TCA cycle
intermediates is influenced by rate-limiting processes beyond mere chemical
exchange across enzymatic reactions. The implication of these results is that
13C NMR is sensitive not only to TCA cycle activity but also to transport
processes for isotope exchange across the mitochondrial membrane. This
finding may provide 13C NMR as a valuable new tool to monitor subcellular
process, which previously could only be studied in isolated mitochondria.
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Chapter 5
Subcellular Transport and the
Effects of Cytosolic Redox State on
Dynamic 13C NMR Spectra
Studies presented in this chapter were aimed at exploring the potential of
using dynamic 13C NMR spectroscopy to observe metabolic communications
between subcellular compartments. Experiments were designed to induce
high cytosolic oxidation-reduction (redox) state by supplying the heart with
exogenous lactate (141). Glutamate enrichment kinetics were found to be
sensitive to changes in malate-aspartate shuttle activity.
5.1 Malate-Aspartate Shuttle Activity and Metabolite Transport at High
Cytosolic Redox State
The carrier that mediates the transport of a-ketoglutarate across the
mitochondrial membrane is part of the redox dependent malate-aspartate
shuttle. In this shuttle, cytosolic oxaloacetate is reduced to malate which
enters the mitochondria where it is reoxidized to oxaloacetate with release of
NADH for reoxidation in the electron transport chain. Efflux of oxaloacetate
from the mitochondria is kinetically limited, so that oxaloacetate is
preferentially transaminated with glutamate to yield aspartate and a-
ketoglutarate. a-Ketoglutarate leaves the mitochondria by a carrier mediated
exchange with malate, while aspartate efflux is coupled with glutamate influx
to complete the cycle. The latter exchange, being electrogenic, is energy
consuming and induces unidirectionality to the malate-aspartate cycle since
aspartate entry into mitochondria is very slow against the membrane
potential (56, 58, 59).
If the transport of a-ketoglutarate is a rate-limiting process in 13C NMR
observation of glutamate labeling, than such observation might be sensitive
to the changes in transport rate. In this study, the potential of using dynamic
13C NMR spectroscopy to observe such process has been explore. Since
malate-aspartate shuttle serves to transfer cytosolic reducing equivalents into
the mitochondria, it is expected that an elevated cytosolic redox state would
stimulate this shuttle and increase the transport rate of a-ketoglutarate.
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In this study, 13C turnover within the glutamate pool of intact,
functioning rabbit hearts oxidizing 13C-enriched substrates was observed with
13C NMR spectroscopy at different cytosolic redox states induced by exogenous
lactate. Isolated rabbit hearts were perfused with 13C-enriched butyrate. The
addition of lactate to the perfusion medium induced a relative increase in
cytosolic redox state (NADH/NAD+) for comparison of 13C kinetics from
hearts at high (2.5 mM lactate, n=5) versus low redox state (no lactate, n=5)
(63, 109). Manipulation of cytosolic redox state during 13C enrichment of the
intramyocardial glutamate pool allowed us to determine whether such NMR
observation of intact, functioning organs are sensitive to redox-dependent
transport activity via the malate-aspartate shuttle.
The presence of lactate in the perfusate served the purpose to enhance the
cytosolic redox state of the myocardium. Lactate in cytoplasm is convert to
pyruvate in a reaction catalyzed by lactate dehydrogenase (LDH). In the
meantime, NAD+ is reduced to NADH.
Lactate + NAD+ < LDH ) Pyruvate + NADH + H +
As the redox state in cytoplasm is elevated, an increase in the malate-
aspartate shuttle activity is expected.
Pyruvate converted from lactate can either enter the TCA cycle through
pyruvate dehydrogenase (PDH) or be transaminated to alanine via alanine
aminotransferase (ATA). PDH is a multi-enzyme complex that catalyzes the
decarboxylation of pyruvate:
Pyruvate + CoA + NAD+  PDH acetyl-CoA + CO 2 + NADH + H +
The acetyl-CoA generated in the above reaction can be further oxidized in
the TCA cycle. The PDH complex exists in active (de-phosphorylated) and
inactive (phosphorylated) forms, the interconversion of which is catalyzed by
a phosphatase and an ATP-dependent kinase respectively (128). Fatty acid
decrease the percent of PDH in the active form (28, 39). Therefore, the activity
of pyruvate dehydrogenase is strongly inhibited. Hence, pyruvate will be
mainly transaminated to alanine by exchanging an amino group with
glutamate:
Pyruvate + glutamate <" AA alanine + a-ketoglutarate
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Under these experimental conditions, the alanine transaminase will
slightly increase the total transaminase flux, and the net enzymatic
interconversion between a-ketoglutarate and glutamate then becomes even
less of a rate-limiting factor for 13C enrichment of glutamate as compared to
net interconversion rate.
5.2 In vitro Results
Table 5.1 Results from in vitro analysis. All data are presented in Mean±SD.
Butyrate Butyrate+Lactate
Glutamate (Cmoles/g dry wt) 24.22±0.75 26.84±4.73
Aspartate (gmoles/g dry wt) 2.09±0.57 1.91±0.46
a-Ketoglutarate (pmoles/g dry wt) 0.32±0.04 0.29±0.06
Citrate (pm~oles/g dry wt) 0.95±0.31 3.29±1.32*
13C-enriched acetyl-CoA, Fc (%) 47.7±4.1 48.0±2.2
Relative anaplerosis, y (%) 13.2+3.4 10.5±5.7
* p<0.05 as compared to hearts perfused with butyrate only.
Steady state metabolite contents are shown in Table 5.1. Lactate induced
an increase in citrate level by more than three-fold, from 0.95 [tmoles/g dry
weight to 3.29 (P=0.005). This shift in metabolite distribution is probably due
to the interaction of the TCA cycle with the malate-aspartate shuttle in
shuttling reducing equivalents from the cytosol into the mitochondria, as is
depicted in Figure 5.1. As more malate enters the mitochondria to be
oxidized to oxaloacetate, there is a transient increase of flux through citrate
synthase accompanied by a transient decrease of flux through a-ketoglutarate
dehydrogenase before a new steady state is established (106, 137). This
imbalance of flux causes the citrate level to accumulate. A continuous
reduction of oxaloacetate to malate in the cytosol also leads to a concomitant
decrease in cytosolic aspartate level from 2.09 to 1.91 pmoles/g dry weight, as
aspartate is deaminated to replenish the oxaloacetate pool. As a result,
glutamate level increased slightly from 24.22 to 26.84 gmoles/g dry weight.
Similar changes were also observed in rat heart when transition was made
from substrate free perfusion to perfusion with glucose and insulin (137), and
in guinea pig heart perfused with lactate only (112).
Page -84-
MITOCHONDRIA
Lactale Malate
Pyruvate Oxaloacet
Glutamate -
Aspartate
Figure 5.1 Interaction of malate-aspartate shuttle with the TCA cycle. Reoxidation of
cytosolic NADH induces a continuous influx of malate into the mitochondria. Citrate
accumulates due to the action of malate dehydrogenase and citrate synthase. Cytosolic
aspartate level decreases as more aspartate is deaminated to replenish the
oxaloacetate pool. Correspondingly, glutamate level increases slightly due to coupled
transamination.
Fraction of 13C-enriched acetyl-CoA (F,) and relative anaplerosis (y) are
also shown in Table 5.1. Both F, and y values are similar in two groups.
Again, the F, values are less than 50% due to the fact that the single labeled
[2-13C] butyrate gives rise to one labeled and one unlabeled acetyl-CoA
molecules. Taking into consideration this partial enrichment of acetyl-CoA,
over 95% of the acetyl-CoA entering the TCA cycle was from butyrate in both
groups, as was expected from the inhibition of pyruvate dehydrogenase by
fatty acid oxidation (28). High resolution 13C NMR spectra showed similar
multiplet structure with and without the presence of lactate (Figure 5.2 and
4.4A). The similarity in these spectra demonstrate that the amount of
butyrate oxidized by hearts with or without additional lactate was essentially
the same. Therefore, hearts oxidizing 13C-enriched butyrate did not utilize
unlabeled exogenous lactate as a carbon source for oxidation.
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Figure 5.2 High resolution 13C spectra of tissue extracts. (A) perfusion with [2-13C]
butyrate and unlabeled lactate; (B) perfusion with [3-13C] lactate and unlabeled
butyrate. The inset in (A) shows similar multiple structures to spectra from heart
perfused with [3- 13C] butyrate only (Figure 4.4A), indicating similar acetyl-CoA
enrichment and anaplerosis. The high intracellular level of labeled lactate and
alanine in (B) indicates a high cytosolic redox potential due to the action of lactate
dehydrogenase. Glucose signal serves as the concentration reference.
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To further document the metabolic fate of the exogenous lactate, another
set of hearts was supplied with 2.5 mM unlabeled butyrate plus 2.5 mM [3-13C]
lactate. Spectra of tissue extracts showed natural abundance level of 13C
enrichment in glutamate (Figure 5.2B), indicating that very little pyruvate
was converted to acetyl-CoA to be oxidized in the TCA cycle. However,
NADH production via conversion of lactate to pyruvate was indicated from
the production of [3- 13C] alanine, as was clearly detected in both 13C (Figure
5.2B) and 1H (Figure 5.3) NMR spectra. Therefore, the effect of exogenous
lactate was to increase cytosolic redox state (NADH/NAD+) during the
oxidation of [2- 13C] butyrate.
13C-LACH
13C-ALA
lII I I \1
12C-LAC
H
1 12 C-AI.A
II JI~ I Y \ I
1.68 1.6 1.52 1.44 1.36
1.68 1.6 1.52 1.44 1.36
ppm
[
13C-LAC
H
13C-ALA
iI,
1.28 1.2I
1.28 1.2
Figure 5.3 Proton spectrum of lactate and alanine. Tissue extract
perfused with 2.5 mM [3-13C] lactate and 2.5 mM unlabeled butyrate.
label from exogenous lactate to the 3-carbons of alanine is evident.
was from heart
Transfer of 13C
5.3 In vivo Results
Oxygen consumption rates (MVO2) were similar between the two groups:
25.32±3.21 imoles/min/g dry weight for hearts oxidizing butyrate only and
24.71±3.06 for hearts perfused with both butyrate and lactate. Mechanical
performance was also similar. Hearts perfused solely with butyrate had an
left ventricular developed pressure (LVDP) of 101±22 mmHg and heart rate
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(HR) of 147±16 beats/min. LVDP and HR for hearts perfused with both
butyrate and lactate were 113±20 mmHg and 151±23 beats/min respectively.
Rate-pressure-products (RPP) were 14,700±3,100 mmHg/min for hearts
oxidizing butyrate only and 17,000±4,300 for hearts perfused with both
butyrate and lactate.
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Figure 5.4 Representative 31p spectra from isolated hearts. Hearts were perfused with
either 2.5 mM [2-13C] butyrate only (A) or 2.5 mM [2-13C] butyrate plus 2.5 mM 12C
lactate (B). Labeled peaks are inorganic phosphate (Pi), phosphocreatine (PCr), and
the three phosphates of ATP (ATPa, ATPp, and ATPy). There is no difference in high
energy phosphate metabolism between the two groups. pH values were also similar as
indicated by the chemical shift of Pi.
Page -88-
~7~-r 7
31p spectra showed no difference in high energy phosphate metabolism
between two groups over the course of perfusion (Figure 5.4). The
phosphocreatine to ATP ratios (PCr/ATP) were similar at 2.27±0.50 with
butyrate only and 2.11±0.23 with both butyrate and lactate. Consistent with
previous findings with lactate perfused hearts (68), no significant changes
were found in intracellular pH determined from the chemical shift of
inorganic phosphate: 7.25±0.20 for hearts perfused with butyrate only and
7.24±0.17 for hearts perfused with butyrate plus lactate.
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Figure 5.5 Effect of lactate on dynamic 13C NMR spectra from isolated hearts. Each
spectrum represents 64 scans over 2.5 minute interval at different time of perfusion.
Peak assignments are: GLU-C2, 2-carbon of glutamate; GLU-C3, 3-carbon of glutamate;
GLU-C4, 4-carbon of glutamate; BU-C2, 2-carbon of butyrate. (A) Spectra from heart
perfused with 2.5 mM [2-13C] butyrate only; (B) Spectra from heart perfused with 2.5
mM [2-13C] butyrate and 2.5 mM unlabeled lactate. Note that heart perfused with both
butyrate and lactate showed more rapid incorporation of 13C into the 4- and 2-carbons of
glutamate.
The evolution of the multiple 13C enrichment sites in glutamate was
monitored by sequential acquisition of 13C NMR spectra from intact hearts.
Representative changes in 13C NMR spectra, reflecting the turnover of carbon
Page -89-
isotope within the glutamate pool, are shown in Fig 5.5. Spectra from heart
perfused with both butyrate and lactate shows early incorporation of 13C label
into the glutamate pool at both 4- and 2-carbons as compared to that of heart
perfused with butyrate only, clearly indicating that cytosolic redox state can
also influence the enrichment rate of glutamate.
Enrichment curves for the 2- and 4-carbons of glutamate are shown in
Figure 5.6, along with the results of the kinetic analysis by least-square fitting
of the model (solid line) to the data shown in the figure. In both groups, the
correlation coefficient between the NMR data and the fitted curves was
greater than 0.98. The obvious difference in enrichment rates between the
two groups, as shown in Figure 5.6, was not accounted for by oxygen
consumption rates. Consistent with similar levels of mechanical work and
respiratory rates, the TCA cycle flux was also very similar between two
groups: 9.66±0.45 gmoles/min/g dry weight with butyrate alone and
10.17±0.29 with both butyrate and lactate. However, the interconversion rate
between (z-ketoglutarate and glutamate increased more than four-fold, from
3.11±0.21 to 14.33±1.97 gmoles/min/g dry weight. These data indicate
increased metabolite transport rate across the mitochondrial membrane due
to stimulated malate-aspartate shuttle activity in response to elevated
cytosolic redox state.
As reducing equivalents generated in the cytosol are shuttled into
mitochondria for electron transfer, an unknown portion of oxygen will be
consumed in oxidizing cytosolic reducing equivalents. Qualitatively, at a
constant rate of ATP generation, increased flux through malate-aspartate
shuttle must be compensated by a decreased flux in the TCA cycle. Therefore,
the use of oxygen consumption to calculate the TCA cycle flux becomes less
reliable in this case. Data fitting was also performed without the constraint
from measured oxygen consumption for the group with both butyrate and
lactate. Both TCA cycle flux and interconversion rate showed no significant
deviation from previous fitting with the constraint. The TCA cycle flux was
slightly lower at 9.31±0.87 imoles/min/g dry weight and the interconversion
rate increased slightly to 18.60±5.32 jmoles/min/g dry weight. Again, this
interconversion rate was more than four-fold higher than that from hearts
perfused only with butyrate.
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Figure 5.6 Time course of 13C enrichment at different cytosolic redox states. Open
circles: 13C enrichment of glutamate at 4-carbon; closed circles: 13C enrichment of
glutamate at 2-carbon. Solid lines are the least-square fittings of the kinetic model to
NMR data. Upper panel: perfusion with 2.5 mM [2- 13C] butyrate only (n=5); lower
panel: perfusion with 2.5 mM [2-13C] butyrate + 2.5 mM unlabeled lactate (n=5).
5.4 Discussion
Studies described in this chapter were designed primarily to investigate
the interaction of malate-aspartate shuttle with the TCA cycle. The results of
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this work show directly, for the first time, that the exchange rates of metabolic
intermediates between subcellular compartments responds to physiological
perturbations of cell metabolism in intact organs. The data also demonstrate
that 13C NMR is sensitive to both chemical exchange and, more importantly,
to the transport of metabolites between subcellular compartments.
While the previous study has shown that the interconversion between x-
ketoglutarate and glutamate involves metabolite transport between
subcellular compartments and is another rate-limiting step in glutamate
enrichment (140), this study further explored this particular component by
introducing metabolic perturbations to change the transport rate. Several
investigators have used transaminase inhibitors to study the effect of changed
interconversion rate on glutamate enrichment kinetics (133, 142). However,
the use of inhibitors to explore the rate-limiting components is inappropriate,
as inhibition will cause any step in the kinetic process, even rapid processes,
to become rate-limiting. The current protocol was designed to probe the
physiological contributions of metabolite transport by stimulating, rather
than inhibiting, this potential rate-determining step.
The stimulation of metabolite exchange across the mitochondrial
membrane was achieved through the activation of the cytosolic redox-
dependent malate-aspartate shuttle activity. This activation occurred via
elevated cytosolic redox state from the addition of lactate (109). During
perfusion with labeled lactate and unlabeled butyrate, NADH production
through the conversion of lactate to pyruvate was indicated from the
production of [3-13C] alanine. The [3-13C] alanine detected by 1H and 13C NMR
documented the reverse flux across the lactate dehydrogenase reaction. The
absence of lactate oxidation through the TCA cycle in the presence of butyrate
is consistent with the inhibition of pyruvate dehydrogenase activity by fatty
acid oxidation (28, 45, 130). Therefore, the major effect of exogenous lactate
was to increase cytosolic redox state (NADH/NAD+). In addition, the
interaction of malate-aspartate shuttle with the TCA cycle induced a
redistribution of metabolites among the TCA cycle intermediates and amino
acid pools.
The influence of cytosolic redox state on the malate-aspartate shuttle
activity was apparent in the observed 13C enrichment of the glutamate pool
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in intact, functioning heart. Least-square fitting of a simple compartment
model to these NMR data shown that the increase in malate-aspartate shuttle
activity induced a more than four-fold increase in the interconversion rate
between a-ketoglutarate and glutamate. The transaminase activity
responsible for the exchange of label between a-ketoglutarate and glutamate
follows simple ping-pong reaction kinetics (33). As was shown in both 31P
spectra and previous experiments, the delivery of exogenous lactate to
healthy, well-perfused myocardium does not exceed the pH buffering capacity
of the cell and thus pH was not a source of variation in enzyme activity in
this study (68). Therefore, without the allosteric regulation of the
transaminase or changes in tissue pH, the observed acceleration in the
interconversion of ca-ketoglutarate and glutamate was achieved by driving
the malate-aspartate shuttle at an elevated cytosolic redox potential with 2.5
mM exogenous lactate (105, 109).
In summary, this study explored the potential of 13C NMR to determine
the rates of metabolite exchange across the mitochondrial membrane in intact
functioning hearts. The results show directly that the NMR observed 13C
turnover in glutamate reflects the adjustments in metabolic communication
between subcellular compartments in response to metabolic state of the cell.
These findings have important impact on future investigations of the
regulation of metabolic activities between subcellular compartments of the
cell in support of the physiological functions in intact tissues, which
previously has only been studied in isolated mitochondria with an artificial
cytosolic environment. More immediately, considerations of additional rate-
limiting steps among the processes contributing to carbon isotope turnover
within the tissue glutamate pool open a new opportunity for current
applications of 13C NMR spectroscopy in the study of metabolic flux.
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Chapter 6
Conclusions and Future Perspectives
Several major conclusions can be drawn from this study. They will be
presented and discussed in this chapter.
First, pre-steady state 13C NMR analysis provides information uniquely
related to metabolic turnover in support of physiological functions. It allows
continual metabolic evaluation of functioning hearts in a nondestructive way
and therefore, can enrich our understanding of the intracellular processes
that occur in response to various metabolic demands of physiological
function. Given the complexity of the information contained in 13C NMR
spectra, a comprehensive evaluation requires mathematical treatment.
However, a comprehensive model needs not be a complicated one. The
kinetic model developed from this work has only nine differential equations
and is the simplest model obtained so far. Yet it is equivalent to other more
complicated models when applied to the analysis of dynamic 13C NMR
spectra. Furthermore, sensitivity analysis indicates that the labeling kinetics
of glutamate is insensitive to changes in metabolite contents of the TCA cycle
intermediates. Therefore, inaccuracies in the measurements of these
metabolites can be tolerated in kinetic analysis.
This simple model should also be readily applicable to in vivo conditions,
provided that constraint parameters are available from appropriate in vivo
monitoring and a priori knowledge of metabolite pool sizes. As indicated by
the study with [2,4-13C] butyrate, the fractional enrichment of acetyl-CoA has
no influence on the kinetics of glutamate labeling. Hence, 13C NMR analysis
of tissue extracts can be avoided while relative anaplerosis can be calculated
from the steady-state enrichment levels of both the 4- can 2-carbons of
glutamate. Furthermore, since the labeling kinetics of glutamate is
minimally influenced by the pool sizes of TCA cycle intermediates and
aspartate, as was shown in sensitivity analysis, only glutamate concentration
needs to be accurately determined. The current model assumes instant
enrichment of acetyl-CoA pool, which is a valid approximation for isolated
heart. However, since in vivo heart derives a significant amount of carbon
source from endogenous triacyglycerides, this assumption may no longer be
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valid. In this case, it is necessary to obtain the 13C enrichment curve of the
plasma. By incorporating the transport of substrate into the model, acetyl-
CoA enrichment can be extrapolated.
Consistent with previous findings about the glutamate-oxaloacetate
transaminase (GOT), the flux through GOT in intact heart is indeed very fast
as compared to the TCA cycle activity. However, the interconversion rate
between ca-ketoglutarate and glutamate was found to be at least 20 times
slower than the flux through GOT. Data from isolated mitochondria indicate
that about 90% glutamate is cytosolic. Hence, this slow interconversion rate is
best explained by the slow transport rate across the mitochondrial membrane.
The slow interconversion rate between (a-ketoglutarate and glutamate also
suggests another rate-limiting step in glutamate enrichment of 13C label.
Thus, it is unlikely that glutamate enrichment is solely determined by the
TCA cycle flux. Therefore, care must be taken in interpreting 13C NMR
spectra of glutamate as a direct index of the TCA cycle activity unless a
comprehensive evaluation is given.
To test whether metabolite transport accounts for the discrepancy between
the transaminase rate and the interconversion rate, the effect of stimulated
malate-aspartate shuttle on 13C NMR observation was examined. Elevated
cytosolic redox state increased the rate of isotope turnover in glutamate.
While the TCA cycle flux was not influenced by the perturbation, the
interconversion rate between a-ketoglutarate and glutamate increased by
more than four folds. Thus, the effect of driving metabolite transport across
the mitochondrial membrane via the redox-dependent malate-aspartate
shuttle was reflected in dynamic 13C NMR data with an increased
interconversion rate between the TCA cycle intermediates and glutamate.
These results show for the first time that dynamic 13C NMR is sensitive not
just to chemical exchange, but also to metabolite transport across the
mitochondrial membrane.
Compartmentation of metabolic processes in living cells represents an
important regulatory mechanism in coordinating energy production to cell
functions. Metabolic communication between subcellular compartments is
achieved largely by selective permeability of membranes to different
metabolites, or carrier mediated transport, which allows for efficient control
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of reaction pathways. Through the adjustment of metabolite distribution
between the mitochondria and cytosol, the metabolic demands of overall
physiological function by the cell can be translated to the energetic machinery
of the mitochondria. The malate-aspartate shuttle interacts directly with the
TCA cycle through carrier mediated transport of ac-ketoglutarate, malate,
aspartate, and glutamate across the mitochondrial membrane. However, the
interaction of the malate-aspartate shuttle with the TCA cycle has only been
studied in isolated mitochondria with an artificial cytosolic environment.
The findings in this study offer an exciting new prospect for studying the
physiochemical regulation between the mitochondrial and cytosolic
compartments in intact, functioning tissues.
One immediate application of the methodologies developed in this study
is the investigation of metabolic activity in diseased heart, such as post-
ischemic heart. It was found that reduced isotope turnover in the glutamate
pool occurs in heart with mechanical dysfunction after brief reversal
ischemia, a disease caused by coronary artery occlusion (45, 67, 71, 132).
Another poorly understood phenomenon, inefficient oxygen utilization in
reperfused heart ("oxygen paradox"), is also related to the metabolic events in
post-ischemic myocardium (26). The relatively normal rate of oxygen
consumption in post-ischemic heart suggests that the TCA cycle flux may be
normal and that a different rate-determining process may have caused the
observed reduction in isotope turnover in glutamate pool. Preliminary study
indicates that while the TCA cycle flux and transaminase activity remain
normal, the rate of metabolite exchange across the mitochondrial membrane
of the intact heart is reduced during post-ischemic contractile dysfunction
(73). Further investigation using 13C spectroscopic methods developed from
this study will allow the potential defects in the oxidative metabolism of post-
ischemic hearts to be elucidated by offering a comprehensive evaluation of
both the biochemical and physiological performances of the heart.
Metabolite contents in the whole cell have been used as the pool sizes in
the kinetic model. Therefore, the interconversion rate in the model is really
a lumped factor that involves both transaminase flux and transport rate. The
model needs to be further developed to incorporate the malate-aspartate
shuttle and to localize the kinetics to the individual transporters so that
absolute flux through the malate-aspartate shuttle and related transporters
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can be determined. Such a model will be similar to that developed by
Chatham et al. (19) yet with fewer equations. In this case, careful quantitative
study of the distribution of intermediary metabolites within the cell will be of
great importance. Several methods have been developed which attempt to
estimate the content of metabolites in cytoplasm and mitochondria (126). Yet
these methods have not reached the state where the conclusions about
metabolite distribution can be accepted with confidence. However, there is
rough agreement among those methods about the gradients for citrate, a-
ketoglutarate, and malate (126), and these data can therefore be incorporated
into the expanded model with confidence. By combining data obtained from
isolated mitochondria study on individual transporter, such development
will allow further insight into the communication and regulation of
metabolic processes in different subcellular compartments.
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Appendix A Biochemical Assays
A.1 Glutamate Assay
Principle:
L-Glutamate + NAD + + H20 ( GDH c a-Ketoglutarate + NADH + H +
NADH + INT + H+  diaphorase - NAD + + Formazan
fomazan is measured in the visible range at 492 nm.
Materials:
Solution #1: potassium phosphate/triethanolamine buffer, pH 8.6; Triton X-100.
Solution #2: diaphorase from pig heart; NAD+; stabilizer.
Solution #3: iodonitro tetrazolium chloride (INT) solution.
Solution #4: glutamate dehydrogenase (GDH) solution.
Procedure:
1. Pipette into cuvettes:
Blank Sample
Distilled H20 1 ml 950 Rl
Solution #1 300 pl 300 •l
Solution #2 100 pl 100 ll
Sample Solution - 50 pl
Solution #3 100 pl 100 pl
2. Mix, after 3 minutes read absorbances (A.) of the solution at 492 nm;
3. Start the readtion by adding 15 ml GDH (solution #4);
4. Mix, wait until reaction has stopped (20 minutes), read absorbance (Af);
Calulation of glutamate concentrations:
V
c= x (A, -4)
exlxv
= 1.50754 x AA(gmoles / ml)
where V = total volume in cuvette (1.5 ml),
I = path length (1 cm),
E = extinction coefficient (19.9 1/pmole/cm),
v = sample volume (50 ml),
AA = change in absorbance.
* AA should be at least 0.100 OD units for accuracy.
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A.2 a-Ketoglutarate Assay
Principle:
a-Ketoglutarate + L-Aspartate - GOT 4 L-Glutamate + Oxaloacetate
Oxaloacetate + NADH + H MDH > L-Malate + NAD +
Buffer components:
Hepes (50 mM) 1.19 gr pH to 7.4;
Mg2C12  (10 mM) 0.203 gr
EDTA (5 mM) 1 ml of 0.5 M
Distilled H20 to 100 ml
Procedures:
1. Determine the exact concentration of an a-ketoglutarate standard solution
(around 0.5 mM) using a spectrophotometer:
* Make an assay cocktail: 10 ml buffer
0.2 ml of 250 mM aspartate
2 mg NADH
20 units malate dehydrogenase (MDH)
* In a 1 ml cuvette, add 1 ml assay cocktail
200 gl sample
* Read absorbance at 340 nm
* Start reaction by adding 2 p1 glutamate-oxaloacetate transaminase (GOT)
* Calculate concentration:
AA Vtotai(1202 9l1)c =- x 'ma (pmoles / ml)6.22 Vsample (200 pl)
2. Fluorometrical determination:
* Set up fluorometer to read excitation at 345 nm, emission at 450 nm
* In a 3 ml cuvette, add 2.5 ml buffer
40 pl 250 mM aspartate
25 pl of 2 mg/ml NADH
2 pl of MDH
200 pl sample
* Read fluorescence to make sure a steady state is obtained
* Start the reaction with 2 •l GOT
* Calculation:
AF +AB V
I AX s X Cstd
l- std Vspl
where AF,, = change in fluoresence in the sample,
AFstd = change in fluoresence in the standard solution,
V8, = sample volume added to cuvette (200 •l),
Vstd = volume of standard solution added to cuvette,
cstd = concentration of the standard solution,
AB = internal blank, i.e. baseline increase with the addition of GOT.
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A.3 Aspartate Assay
Principle:
L-Aspartate + a-Ketoglutarate ( GOT - Oxaloacetate + L-Glutamate
Oxaloacetate + NADH + H' MDH - L-Malate + NAD +
Buffer components:
Tra (50 mM)
MgSO4 (5 mM)
EDTA (5 mM)
Procedures:
1. Determine the exact concentration of an aspartate standard solution (around 0.5
mM) using a spectrophotometer:
* In a 1 ml cuvette, add 1.5 ml buffer
0.1 ml standard aspartate (0.5 mM)
50 gl NADH (2 mg/ml)
50 gl a-ketoglutarate (100 mM)
5 pl MDH (1 mg/ml)
* Read absorbance at 340 nm
* Start reaction by adding 5 gl glutamate-oxaloacetate transaminase (GOT)
* Calculate concentration:
c = - x a (Amoles / ml)6.22 Vsample (0.1 ml)
2. Fluorometrical determination:
* Set up fluometer to read excitation at 345 nm, emission at 450 nm
* In a 3 ml cuvette, add 2.0 ml buffer
20 gl 100 mM a-ketoglutarate
20 gl of 2 mg/ml NADH
5 gl of MDH
200 Rl sample (50 ml for 0.5 mM standard aspartate)
* Read fluorescence to make sure a steady state is obtained
* Start the reaction with 5 gl GOT
* Calculation:
AFsp + AB td
spl ~std + AB V std
where AFL I = change in fluoresence in the sample,
AFstd = change in fluoresence in the standard solution,
VSP, = sample volume added to cuvette (200 gl),
Vstd = volume of standard solution added to cuvette,
Cstd = concentration of the standard solution,
AB = internal blank, i.e. baseline increase with the addition of GOT.
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A.4 Citrate Assay
Principle:
Citrate ( CLMg++ ) Oxaloacetate + Acetate
Oxaloacetate + NADH + H÷ MDH - L-Malate + NAD +
Buffer:
Hepes
Mg2C12
EDTA
Distilled
(50 mM)
(10 mM)
(5 mM)
H20 to 100 ml
Procedures:
* Make an assay cocktail:
* In a 1 ml cuvette, add
1.19 gr
0.203 gr
1 ml of 0.5 M
pH to 7.4
10ml buffer
2 mg NADH
20 units MDH (10 pl)
1 ml assay cocktail
300 p.l sample
Read absorbance at 340 nm
Start reaction with 10 pll citrate lyase
Calculate concentration:
C = xV (lmoles / ml)
6.22 Vsample(300 pl)
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Appendix B. MATLAB Programs for the Analysis of 13C NMR
Spectra from Tissue Extracts
% INVITRO.m:
% Analysis of the in vitro spectrum to determine Fc and y
% (ref. CR Malloy, JBC 263, 1988)
clg
global data plthd plthddat hd_textl hd_text2 hd_text3 hd_text4 hd_text5 hd_text6
% Glutamate C2
c2ql=2.90; c2q2=0.92; c2q3=2.55; c2q4=3.39;
c2d121=4.10; c2d122=7.01;
c2d231=19.81; c2d232=21.04;
c2s=57.73;
c2d12=c2d121+c2d122;
c2d23=c2d231+c2d232;
c2q=c2ql+c2q2+c2q3+c2q4;
c2=c2s+c2d12+c2d23+c2q;
% Glutamate C3
c3s=36.31;
c3dl=30.86; c3d2=29.53;
c3tl=5.59; c3t2=13.06; c3t3=6.89;
c3t=c3tl+c3t2+c3t3;
c3=c3t+c3s+c3dl+c3d2;
% Glutamate C4
c4s=100.00;
c4dl=28.78; c4d2=35.92;
c4d34=c4dl+c4d2;
c4=c4s+c4d34;
data=zeros(6,2);
data(:,1)=(1:6)';
data(1,2)=c2s/c2;
data(2,2)=c2d12/c2;
data(3,2)=c2d23/c2;
data(4,2)=c3s/c3;
data(5,2)=c3t/c3;
data(6,2)=c4d34/c4;
% Initial Fc and y values for data fitting
pO=[.l 0.11];
% Setup graphics
figure(l)
set(1,'Name','In vitro Analysis: Fc & y');
C4_fieldl=uicontrol('Style','edit','Position',[.05 .12 .07 .05],...
'Units','normalized','String',num2str(c4dl),...
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'CallBack','c4dl=str2num(get(C4_fieldl,"String")); extdat');
C4_field2=uicontrol('Style','edit','Position',[.12 .12 .07 .05],...
'BackgroundColor','c','Units','normalized','String',num2str(c4s),...
'CallBack','c4s=str2num(get(C4_field2,"String")); extdat');
C4_field3=uicontrol('Style','edit','Position',[.19 .12 .07 .05],...
'Units','normalized','String',num2str(c4d2),...
'CallBack','c4d2=str2num(get(C4_field3,"String")); extdat');
C3_fieldl=uicontrol('Style','edit','Position',[.33 .12 .07 .05],...
'BackgroundColor', 'y', 'Units','normalized','String',num2str(c3tl),...
'CallBack','c3tl=str2num(get(C3_fieldl,"String")); extdat');
C3_field2=uicontrol('Style','edit','Position',[.40 .12 .07 .05],...
'Units','normalized','String',num2str(c3dl),...
'CallBack','c3dl=str2num(get(C3_field2,"String")); extdat');
C3_field3=uicontrol('Style','edit','Position',[.47 .12 .07 .05],...
'BackgroundColor','c','Units','normalized','String',num2str(c3s),...
'CallBack','c3s=str2num(get(C3_field3,"String")); extdat');
C3_field4=uicontrol('Style','edit','Position',[.54 .12 .07 .05],...
'BackgroundColor','y','Units','normalized','String',num2str(c3t2),...
'CallBack','c3t2=str2num(get(C3_field4,"String")); extdat');
C3_field5=uicontrol('Style','edit','Position',[.61 .12 .07 .05],...
'Units','normalized','String',num2str(c3d2),...
'CallBack','c3d2=str2num(get(C3_field5,"String")); extdat');
C3_field6=uicontrol('Style','edit','Position',[.68 .12 .07 .05],...
'BackgroundColor','y','Units','normalized','String',num2str(c3t3),...
'CallBack','c3t3=str2num(get(C3_field6,"String")); extdat');
C2_fieldl=uicontrol('Style','edit','Position',[.05 .05 .07 .05],...
'Units','normalized','String',num2str(c2ql),...
'CallBack','c2ql=str2num(get(C2_fieldl,"String")); extdat');
C2_field2=uicontrol('Style','edit','Position',[.12 .05 .07 .05],...
'BackgroundColor','y','Units','normalized','String',num2str(c2dl21),...
'CallBack','c2dl21=str2num(get(C2_field2,"String")); extdat');
C2_field3=uicontrol('Style','edit','Position',[.19 .05 .07 .05],...
'BackgroundColor','m','Units','normalized','String',num2str(c2d231),...
'CallBack','c2d231=str2num(get(C2_field3,"String")); extdat');
C2_field4=uicontrol('Style','edit','Position',[.26 .05 .07 .05],...
'Units','normalized','String',num2str(c2q2),...
'CallBack','c2q2=str2num(get(C2_field4,"String")); extdat');
C2_field5=uicontrol('Style','edit','Position',[.33 .05 .07 .05],...
'BackgroundColor','c','Units','normalized','String',num2str(c2s),...
'CallBack','c2s=str2num(get(C2_field5,"String")); extdat');
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C2_field6=uicontrol('Style','edit','Position',[.40 .05 .07 .05],...
'Units','normalized','String',num2str(c2q3),...
'CallBack','c2q3=str2num(get(C2_field6,"String")); extdat');
C2_field7=uicontrol('Style','edit','Position',[.47 .05 .07 .05],...
'BackgroundColor','m','Units','normalized','String',num2str(c2d232),...
'CallBack','c2d232=str2num(get(C2_field7,"String")); extdat');
C2_field8=uicontrol('Style','edit','Position',[.54 .05 .07 .05],...
'BackgroundColor','y','Units','normalized','String',num2str(c2d122),...
'CallBack','c2dl22=str2num(get(C2_field8,"String")); extdat');
C2_field9=uicontrol('Style','edit','Position',[.61 .05 .07 .05],...
'Units','normalized','String',num2str(c2q4),...
'CallBack','c2q4=str2num(get(C2_field9,"String")); extdat');
C2S_field=uicontrol('Style','text','Position',[.78 .85 .20 .08],...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C2S=' num2str(data(1,2))],...
'CallBack','extdat');
C2D12_field=uicontrol('Style','text','Position',[.78 .75 .20 .08],...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C2D12=' num2str(data(2,2))],...
'CallBack','extdat');
C2D23_field=uicontrol('Style','text','Position',[.78 .65 .20 .08],...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C2D23=' num2str(data(3,2))],...
'CallBack','extdat');
C3S_field=uicontrol('Style','text','Position',[.78 .55 .20 .08],...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C3S=' num2str(data(4,2))],...
'CallBack','extdat');
C3T_field=uicontrol('Style','text','Position',[.78 .45 .20 .081,...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C3T=' num2str(data(5,2))],...
'CallBack','extdat');
C4D34_field=uicontrol('Style','text','Position',[.78 .35 .20 .08],...
'Units','normalized','BackgroundColor',[.5 .7 .5],...
'ForegroundColor','black','String',['C4D=' num2str(data(6,2))],...
'CallBack','extdat');
Fc_field=uicontrol('Style','text','Position',[.78 .25 .20 .08],...
'Units','normalized','BackgroundColor','red',...
'ForegroundColor','white','String','Fc=0.0',...
'CallBack','extdat');
y_field=uicontrol('Style','text','Position',[.78 .15 .20 .08],...
'Units','normalized','BackgroundColor','red',...
'ForegroundColor','white','String','y=0.0',...
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'CallBack','extdat');
int_text=uicontrol('Style','text','Position',[.05 .20 .16 .05],...
'Units','normalized','BackgroundColor','black',...
'ForegroundColor','white','String','Initial Fc & y:');
p_fieldl=uicontrol('Style','edit','Position',[.22 .20 .10 .05],...
'Units','normalized','String',num2str(pO(1)),...
'CallBack','pO(1)=str2num(get(p_fieldl,"String")); extfit');
pfield2=uicontrol('Style','edit','Position',[.342 .20 .10 .05],...
'Units','normalized','String',num2str(pO(2)),...
'CallBack','p0(2)=str2num(get(p_field2,"String")); extfit');
start_button=uicontrol('Style','Pushbutton','Position',[.85 .04 .12 .08],...
'Units','normalized','Callback','extfit','String','Start');
ax_smith=axes('Position',[.1 .30 .6 .65],'XLim',[1 6],'YLim',[0 1]);
plthddat=plot(data(:,1),data(:,2),'r.','MarkerSize',25,'EraseMode','xor');
hd_textl=text(1.1,data(1,2),'C2S','EraseMode','xor');
hd_text2=text(2.1,data(2,2),'C2D12','EraseMode','xor');
hd_text3=text(3.1,data(3,2),'C2D23','EraseMode','xor');
hd_text4=text(4.1,data(4,2),'C3S','EraseMode','xor');
hd_text5=text(5.1,data(5,2),'C3T','EraseMode','xor');
hd_text6=text(5.5,data(6,2),'C4D','EraseMode','xor');
hold on
plthd=plot(data(:,l),data(:,2),'EraseMode','xor');
axis([1 6 -.05 1]);
drawnow
% EXTDAT.m
% called by invitro.m to calculate C2S, C2D12, C2D23, C3S, C3T, and C4D
% from the in vitro carbon-13 spectrum and update the graphic display
global data plthd plthd_dat hd_textl hd_text2 hd_text3 hd_text4 hd_text5 hd_text6
c2d12=c2d121+c2d122;
c2d23=c2d231+c2d232;
c2q=c2ql+c2q2+c2q3+c2q4;
c2=c2s+c2d12+c2d23+c2q;
c3t=c3tl+c3t2+c3t3;
c3=c3t+c3s+c3dl+c3d2;
c4d34=c4dl+c4d2;
c4=c4s+c4d34;
data=zeros(6,2);
data(:,1)=(1:6)';
data(1,2)=c2s/c2;
data(2,2)=c2d12/c2;
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data(3,2)=c2d23/c2;
data(4,2)=c3s/c3;
data(5,2)=c3t/c3;
data(6,2)=c4d34/c4;
set(C2S_field,'String',['C2S=' num2str(data(1,2))]);
set(hd_textl,'Position',[1.1 data(1,2)]);
set(C2D12_field,'String',['C2D12=' num2str(data(2,2))]);
set(hd_text2,'Position',[2.1 data(2,2)]);
set(C2D23_field,'String',['C2D23=' num2str(data(3,2))]);
set(hd_text3,'Position',[3.1 data(3,2)]);
set(C3S_field,'String',['C3S=' num2str(data(4,2))]);
set(hd_text4,'Position',[4.1 data(4,2)]);
set(C3T_field,'String',['C3T=' num2str(data(5,2))]);
set(hd_text5,'Position',[5.1 data(5,2)]);
set(C4D34_field,'String',['C4D34=' num2str(data(6,2))]);
set(hd_text6,'Position',[5.3 data(6,2)]);
set(plthd_.dat,'ydata',data(:,2))
% EXTFIT.m
% called by INVITRO.m to determine Fc & y by data fitting
global data plthd
trace=1;
tol=0.0001;
p0
p=fmins('malloy',p0,[trace tol]);
set(Fc_field,'String',['Fc=' num2str(p(1))]);
set(y_field,'String',['y=' num2str(p(2))]);
drawnow
% MALLOY.m
% objective function to be optimized by EXTFIT.m
function err=malloy(p)
global data plthd
Fc=p(1);
y=p(2);
yl=y+l;
y2=2*ylA2;
FcO=1-Fc;
s=zeros(6,1);
s(1)=(y2-2*Fc*yl-Fc+FcA2)/y2;
s(2)=FcO*Fc/y2;
s(3)=Fc*(2*yl-Fc)/y2;
s(4)=Fc0*(FcO+y)/yl;
s(5)=FcA2/yl;
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s(6)=Fc/(2*y+l);
set(plthd,'ydata',s)
%disp('Press any key to continue ...')
%pause
err=sum((data(:,2)-s).*(data(:,2)-s));
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Appendix C Optimization and Simulation Programs
%TCAVF.m: Optimization program used to optimize flux parameters that determine the
% labeling kinetics of glutamate C-4 and C-2 using Levenberg-Marquardt least
% square optimization method. Simulation of presteady state labeling of C13 in
% the TCA cycle metabolites is performed by solving the differential equations
% that describe the labeling and the gradient of labeling.
clear
global Fc Y V F CIT aKG GLU MAL OAA ASP VO V_err Vweight
global c4_dat c2_dat c4_std c2_std c4_err c2_err
global c4_hdl c2_hdl tlt glu4 glu2 akg4 akg2
global time tf ts M tlt
% Read in parameters
[prm, prmfile]=getfile('Name of the parameter file:','*.prm');
CIT=prm(1);
aKG=prm(2);
GLU=prm(3);
MAL=prm(4);
OAA=prm(5);
ASP=prm(6);
Fc=prm(7);
Y=prm(8);
Fc_err=prm(9);
VO=prm(10);
V_err=prm(11);
V_weight=prm(12);
% Read in NMR data
[data,data_file]=getfile('Name of the data file:','*.dat');
[M, N]=size(data);
time = data(:,1);
tf=time;
ts=tf-tf(1);
maxglu=max(data(:,2));
c4_dat = data(:,2)*(Fc+Fc_err)/maxglu;
c4_std = data(:,3)*Fc; .
c2_dat = data(:,4)*(Fc+Fc_err)/maxglu;
c2_std = data(:,5)*Fc;
c4_stdm=max(c4_std);
c2_stdm=max(c2_std);
c4_err=c4_std+(c4_std<2e-2)*c4_stdm;
c2_err=c2_std+(c2_std<2e-2)*c2_stdm;
savefile=input('Save in *.mat file? ','s');
% Plot the glutamate enrichment curves
figure(l)
clf
set(1,'Name','Curve Fitting','Position',[5 400 350 500])
ymax=0.5+(Fc>0.5)*0.5;
figure(2)
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clf
set(2,'Name','13C Labeling & Gradient Curve','Position',[380 480 600 250])
figure(1)
subplot(2,1,1)
errorbar(time, c4_dat, c4_std)
hold on
plot(time,c4_dat,'k-')
c4_hdl=plot(time,c4_dat,'c-','EraseMode','xor');
plot(time,c4_dat,'r.', 'MarkerSize',15)
grid
xlabel('time(min)')
ylabel('C4 Concentration')
title(data_file)
axis([0 time(M) 0 ymax])
subplot(2,1,2)
errorbar(time, c2_dat, c2_std)
hold on
plot(time,c2_dat,'k-')
c2_hdl=plot(time,c2_dat,'c-','EraseMode','xor');
plot(time,c2_dat,'r.', 'MarkerSize',15,'EraseMode','none')
grid
xlabel('time(min)')
ylabel('C2 Concentration')
axis([0 time(M) 0 ymax])
disp('Now, start optimization ...')
% p vector:
% p(2) = V -- TCA flux
% p(1) = F -- interconversion flux
p0=input('Initial parameters ([F1 V-TCA])?');
tic
options=[];
options(1)=l;
options(2)=le-3;
options(3)=le-2;
options(16)=le-2;
[p,OPTIONS,SSQ,J]=nleastsq('simu9',pO,options,'tca9_grad');
covar=covariance_new(p,SSQ,J)
error=OPTIONS(8);
err4=sum(SSQ(1:M).*SSQ(1:M));
err2=sum(SSQ(M+1:2*M).*SSQ(M+1:2*M));
disp(['TCAflux=' num2str(p(2))', aKG<->GLU=' num2str(p(1))])
disp(['err4=' num2str(err4) ', err2=' num2str(err2)])
simu_time=toc/60
eval(['save ' savefile ' ;']);
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%SIMU9.m: simulation of presteady-state labeling of C13 in TCA cycle metabolits.
ssq returns the cost function that also includes the penalty term for MVO2.
function ssq = simu9(p)
TCA intermediates:
CIT: citrate;
aKG: a-ketoglutarate;
GLU: glutamate;
MAL: malate;
OAA: oxaloacetate;
ASP: aspartate;
global Fc Y V F CIT aKG GLU MAL OAA ASP VO V_err Vweight
global c4_dat c2_dat c4_std c2_std c4_err c2_err
global c4_hdl c2_hdl tlt glu4 glu2 akg4 akg2
global time tf ts M
V=p(2);
F=p(1);
% y vextor of%
%
%
%
%
%
%
%
%
fractional enrichment levels:
yd(1) = CIT-C4
yd(2) = aKG-C4
yd(3) = GLU-C4
yd(4) = CIT-C2
yd(5) = aKG-C2
yd(6) = GLU-C2
yd(7) = MAL-C3
yd(8) = OAA-C3
yd(9) = ASP-C3
t0=0.0;
tfinal=time(M);
ydO = zeros(9,1);
tol=le-3;
[td,yd]=ode45('model9',tO,tfinal,ydO,tol);
c4_sim=yd(:,3);
c2_sim=yd(:,6);
glu4=(mgh_integrate(td,c4_sim,tf)-mgh_integrate(td,c4-sim,ts))/time(1);
glu2=(mgh_integrate(td,c2_sim,tf)-mghintegrate(td,c2_sim,ts)) /time(1);
akg4=(mghintegrate(td,yd(:,2),tf)-mgh_integrate(td,yd(:,2),ts)) /time(1);
akg2=(mgh_integrate(td,yd(:,5),tf)-mgh_integrate(td,yd(:,5),ts)) /time(l);
ssq=[(glu4-c4_dat)./c4_err; (glu2-c2_dat)./c2_err; V_weight*(V-VO)/Verr];
figure(1)
subplot(2,1,1)
tlt=['V=' num2str(V) ', F=' num2str(F)];
title(tlt)
set(c4_hdl,'ydata',glu4)
set(c2 hdl,'ydata',glu2)
figure(2)
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subplot(1,2,1)
plot(td,yd(:,l),'g-',td,yd(:,2),'r-',td,yd(:,3),'c-', ...
td,yd(:,4),'g:',td,yd(:,5),'r:',td,yd(:,6),'c:');
ylabel(tlt)
grid
%MODEL9.m: Mathematical description of the kinetic model of the TCA cycle enrichment
% kinetics (9 equations).
function ydp = model9(td,yd)
global Fc Y V F CIT aKG GLU MAL OAA ASP
% yd vextor of fractional enrichment levels:
yd(1)
yd(2)
yd(3)
yd(4)
yd(5)
yd(6)
yd(7)
yd(8)
yd(9)
= CIT-C4
= aKG-C4
= GLU-C4
= CIT-C3
= aKG-C3
= GLU-C3
= MAL-C3
= OAA-C3
= ASP-C3
B=zeros(9,9);
B(1,1)=-V/CIT;
B(2,1)=V/aKG;
B(3,2)=F/GLU;
B(4,4)=-V/CIT;
B(5,4)=V/aKG;
B(6,5)=F/GLU;
B(7,2)=V/2/MAL;
B(8,7)=V/OAA;
B(9,8)=F/ASP;
B(2,2)=-(F+V)/aKG;
B(3,3)=-F/GLU;
B(4,8)=V/CIT;
B(5,5)=-(F+V)/aKG;
B(6,6)=-F/GLU;
B(7,5)=V/2/MAL;
B(8,8)=-(F+V)/OAA;
B(9,9)=-F/ASP;
B(2,3)=F/aKG;
B(5,6)=F/aKG;
B(7,7)=-(1+Y)*V/MAL;
B(8,9)=F/OAA;
ui=zeros(9,1);
ui(1,1)=V*Fc/CIT;
ydp=B*[yd(1),yd(2),yd(3),yd(4),yd(5),yd(6),yd(7),yd(8),yd(9)]'+ui;
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% CIT-C4
% aKG-C4
% GLU-C4
% CIT-C3
% aKG-C3
% GLU-C3
% MAL-C3
% OAA-C3
% ASP-C3
%TCA9_GRAD.m: gradient(d*/dF) and (d*/dV) of TCA model.
function returns a transposed Jacobian matrix:
df/dF
df/dV
0
1/ V_err
function glu_dFdV=tca9_grad(p)
% y vextor of%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
fractional enrichment levels:
y(l) = CIT-C4
y(2) = aKG-C4
y(3) = GLU-C4
y(4) = CIT-C3
y(5) = aKG-C3
y(6) = GLU-C3
y(7) = MAL-C3
y(8) = OAA-C3
y(9) = ASP-C3
y(10) = d(CIT-C4)/dF
y(11) = d(aKG-C4)/dF
y(12) = d(GLU-C4)/dF
y(13) = d(CIT-C3)/dF
y(14) = d(aKG-C3)/dF
y(15) = d(GLU-C3)/dF
y(16) = d(MAL-C3)/dF
y(17) = d(OAA-C3)/dF
y(18) = d(ASP-C3)/dF
y(19) = d(CIT-C4)/dV
y(20) = d(aKG-C4)/dV
y(21) = d(GLU-C4)/dV
y(22) = d(CIT-C3)/dV
y(23) = d(aKG-C3)/dV
y(24) = d(GLU-C3)/dV
y(25) = d(MAL-C3)/dV
y(26) = d(OAA-C3)/dV
y(27) = d(ASP-C3)/dV
global Fc Y V F CIT aKG GLU MAL OAA ASP VO V_err
global c4_dat c2_dat c4_std c2_std c4_err c2_err
global time tf ts M tit
t0=0.0;
tfinal=time(M);
yO=zeros(27,1);
tol=le-3;
V=p(2);
F=p(1);
[t,y] =ode45('model_grad',tO,tfinal,yO,tol);
glu4-df=((mghintegrate(t,y(:,12),tf)-mghintegrate(t,y(:,12),ts))/time(1)). /c4_err;
glu2_df=((mgh_integrate(t,y(:,15),tf)-mghintegrate(t,y(:,15),ts))/time(1))./c2_err;
glu4-dv=((mghintegrate(t,y(:,21),tf)-mgh-integrate(t,y(:,21),ts))/time(1)). /c4err;
glu2_dv=((mghintegrate(t,y(:,24),tf)-mgh-integrate(t,y(:,24),ts)) /time(1))./ c2_err;
gludFdV=[glu4_df' glu2_df' 0.0; glu4_dv' glu2_dv' 1/V_err];
%size(glu_dF)
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figure(2)
subplot(1,2,2)
plot(time,glu4_df,'m-',time,glu4_dv,'c-', time,glu2_df,'m--',time,glu2_dv,'c--');
grid
ylabel(tlt)
%MODEL_GRAD.m: Mathematical description of the kinetic model of TCA
% cycle metabolism with gradient calculated for optimization
function yp = model_grad(t,y)
% y vextor of fractional enrichment levels:
% y(1) = CIT-C4
% y(2) = aKG-C4
% y(3) = GLU-C4
% y(4) = CIT-C3
% y(5) = aKG-C3
% y(6) = GLU-C3
% y(7) = MAL-C3
% y(8) = OAA-C3
% y(9) = ASP-C3
% y(10) = d(CIT-C4)/dF
% y(11) = d(aKG-C4)/dF
% y(12) = d(GLU-C4)/dF
% y(13) = d(CIT-C3)/dF
% y(14) = d(aKG-C3)/dF
% y(15) = d(GLU-C3)/dF
% y(16) = d(MAL-C3)/dF
% y(17) = d(OAA-C3)/dF
% y(18) = d(ASP-C3)/dF
% y(19) = d(CIT-C4)/dV
% y(20) = d(aKG-C4)/dV
% y(21) = d(GLU-C4)/dV
% y(22) = d(CIT-C3)/dV
% y(23) = d(aKG-C3)/dV
% y(24) = d(GLU-C3)/dV
% y(25) = d(MAL-C3)/dV
% y(26) = d(OAA-C3)/dV
% y(27) = d(ASP-C3)/dV
global Fc Y V F CIT aKG GLU MAL OAA ASP
A=zeros(27,27);
A(1,1)=-V/CIT;
A(2,1)=V/aKG;
A(3,2)=F/GLU;
A(4,4)=-V/CIT;
A(5,4)=V/aKG;
A(6,5)=F/GLU;
A(7,2)=V/2/MAL;
A(8,7)=V/OAA;
A(9,8)=F/ASP;
A(2,2)=-(F+V)/aKG;
A(3,3)=-F/GLU;
A(4,8)=V/CIT;
A(5,5)=-(F+V) /aKG;
A(6,6)=-F/GLU;
A(7,5)=V/2/MAL;
A(8,8)=-(F+V)/OAA;
A(9,9)=-F/ASP;
A(2,3)=F/aKG;
A(5,6)=F/aKG;
A(7,7)=-(1+Y)*V/MAL;
A(8,9)=F/OAA;
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% CIT-C4
% aKG-C4
% GLU-C4
% CIT-C3
% aKG-C3
% GLU-C3
% MAL-C3
% OAA-C3
% ASP-C3
A(10,10)=-V/CIT;
A(11,2)=-1/ aKG;
A(11,10)=V/aKG;
A(11,12)=F/aKG;
A(12,2)=1/GLU;
A(12,11)=F/GLU;
A(13,13)=-V/CIT;
A(14,5)=-1/aKG;
A(14,13)=V/aKG;
A(14,15)=F/aKG;
A(15,5)=1 /GLU;
A(15,14)=F/GLU;
A(16,11)=V/2/MAL;
A(16,16)=-(1 +Y)*V/MAL;
A(17,8)=-1/OAA;
A(17,16)=V/OAA;
A(17,18)=F/OAA;
A(18,8)=1/ASP;
A(18,17)=F/ASP;
A(19,1)=-1/CIT;
A(20,1)=1 /aKG;
A(20,19)=V/aKG;
A(20,21)=F/aKG;
A(21,20)=F/GLU;
A(22,4)=-1/CIT;
A(22,22)=-V/CIT;
A(23,4)=1/aKG;
A(23,22)=V/aKG;
A(23,24)=F/aKG;
A(24,23)=F/GLU;
A(25,2)=1/2/MAL;
A(25,7)=-(1+Y) /MAL;
A(25,23)=V/2/MAL;
A(26,7)=1/ OAA;
A(26,25)=V/OAA;
A(26,27)=F/OAA;
A(27,26)=F/ASP;
A(11,3)=1/aKG;
A(11,11)=-(F+V)/aKG;
A(12,3)=-1 /GLU;
A(12,12)=-F/GLU;
A(13,17)=V/CIT;
A(14,6)=1/aKG;
A(14,14)=-(F+V)/aKG;
A(15,6)=-1/GLU;
A(15,15)=-F/GLU;
A(16,14)=V/2/MAL;
A(17,9)=1/OAA;
A(17,17)=-(F+V) /OAA;
A(18,9)=-1 /ASP;
A(18,18)=-F/ASP;
A(19,19)=-V/CIT;
A(20,2)=-1 /aKG;
A(20,20)=-(F+V) / aKG;
A(21,21)=-F/GLU;
A(22,8)=1/ CIT;
A(22,26)=V/CIT;
A(23,5)=-1 / aKG;
A(23,23)=-(F+V)/ aKG;
A(24,24)=-F/GLU;
A(25,5)=1/2/MAL;
A(25,20)=V/2/MAL;
A(25,25)=-(1 +Y)*V/MAL;
A(26,8)=-1/ OAA;
A(26,26)=-(F+V)/OAA;
A(27,27)=-F/ASP;
% d(CIT-C4)/dF
% d(aKG-C4)/dF
% d(GLU-C4)/dF
% d(CIT-C3)/dF
% d(aKG-C3)/dF
% d(GLU-C3)/dF
% d(MAL-C3)/dF
% d(OAA-C3)/dF
% d(ASP-C3)/dF
% d(CIT-C4)/dV
% d(aKG-C4)/dV
% d(GLU-C4)/dV
% d(CIT-C3)/dV
% d(aKG-C3)/dV
% d(GLU-C3)/dV
% d(MAL-C3)/dV
% d(OAA-C3)/dV
% d(ASP-C3)/dV
u=zeros(27,1);
u(1,1)=V*Fc/CIT;
u(19,1)=Fc/CIT;
yp=A*[y(1),y(2),y(3),y(4),y(5),y(6),y(7),y(8),y(9),y(10), 
.
y(11),y(12),y(13),y(14),y(15),y(16),y(17),y(18), ...
y(19 ),y(2 0),y(2 1),y(22),y(23),y(24),y(25),y(26),y(27)]'+u;
Page -126-
